The pathogenicity of SARS-CoV-2 in hACE2 transgenic r

Nature

583, 830-833

DOI: 10.1038/s41586-020-2312-y

Citation Report

#	Article	IF	Citations
1	Predicting susceptibility to SARSâ€CoVâ€2 infection based on structural differences in ACE2 across species. FASEB Journal, 2020, 34, 15946-15960.	0.2	44
2	Pigs are not susceptible to SARSâ€CoVâ€2 infection but are a model for viral immunogenicity studies. Transboundary and Emerging Diseases, 2021, 68, 1721-1725.	1.3	51
3	Severe Acute Respiratory Syndrome Coronavirus 2, COVID-19, and the Renin-Angiotensin System. Hypertension, 2020, 76, 1350-1367.	1.3	46
4	The Coronaviruses of Animals and Birds: Their Zoonosis, Vaccines, and Models for SARS-CoV and SARS-CoV2. Frontiers in Veterinary Science, 2020, 7, 582287.	0.9	60
5	Evidence of a wide gap between COVID-19 in humans and animal models: a systematic review. Critical Care, 2020, 24, 594.	2.5	34
6	COVID-19 in children: Could pertussis vaccine play the protective role?. Medical Hypotheses, 2020, 145, 110305.	0.8	8
7	Assessing the SARS-CoV-2 threat to wildlife: Potential risk to a broad range of mammals. Perspectives in Ecology and Conservation, 2020, 18, 223-234.	1.0	23
8	SARS-CoV-2 host tropism: An in silico analysis of the main cellular factors. Virus Research, 2020, 289, 198154.	1.1	14
9	Comparative docking studies to understand the binding affinity of nicotine with soluble ACE2 (sACE2)-SARS-CoV-2 complex over sACE2. Toxicology Reports, 2020, 7, 1366-1372.	1.6	9
10	A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures. Nature, 2020, 586, 560-566.	13.7	527
11	A Mouse-Adapted SARS-CoV-2 Induces Acute Lung Injury and Mortality in Standard Laboratory Mice. Cell, 2020, 183, 1070-1085.e12.	13.5	472
12	Angiotensin-converting enzymes (ACE, ACE2) gene variants and COVID-19 outcome. Gene, 2020, 762, 145102.	1.0	154
13	Structural and functional modelling of SARS-CoV-2 entry in animal models. Scientific Reports, 2020, 10, 15917.	1.6	53
14	Toward Understanding Molecular Bases for Biological Diversification of Human Coronaviruses: Present Status and Future Perspectives. Frontiers in Microbiology, 2020, 11, 2016.	1.5	11
15	Experimental Models for the Study of Central Nervous System Infection by SARS-CoV-2. Frontiers in Immunology, 2020, 11, 2163.	2.2	27
16	ACE2 mouse models: a toolbox for cardiovascular and pulmonary research. Nature Communications, 2020, 11, 5165.	5.8	51
17	Comparison of transgenic and adenovirus hACE2 mouse models for SARS-CoV-2 infection. Emerging Microbes and Infections, 2020, 9, 2433-2445.	3.0	153
18	2020 update on human coronaviruses: One health, one world. Medicine in Novel Technology and Devices, 2020, 8, 100043.	0.9	21

#	Article	IF	Citations
19	Three-Dimensional Human Alveolar Stem Cell Culture Models Reveal Infection Response to SARS-CoV-2. Cell Stem Cell, 2020, 27, 905-919.e10.	5.2	195
20	Vascular Events, Vascular Disease and Vascular Risk Factorsâ€"Strongly Intertwined with COVID-19. Current Treatment Options in Neurology, 2020, 22, 40.	0.7	10
21	A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity. Nature, 2020, 586, 572-577.	13.7	630
22	SARS-CoV-2 vaccines in development. Nature, 2020, 586, 516-527.	13.7	1,659
23	Mechanisms of SARS-CoV-2 Transmission and Pathogenesis. Trends in Immunology, 2020, 41, 1100-1115.	2.9	794
24	Animal models for COVID-19. Nature, 2020, 586, 509-515.	13.7	705
25	Severe aortic stenosis patient risk during the COVID-19 pandemic. Open Heart, 2020, 7, e001355.	0.9	2
26	Characterization of local SARS-CoV-2 isolates and pathogenicity in IFNARâ˜'/- mice. Heliyon, 2020, 6, e05116.	1.4	17
27	Decoy nanoparticles protect against COVID-19 by concurrently adsorbing viruses and inflammatory cytokines. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 27141-27147.	3.3	173
28	COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives. Nature Reviews Cardiology, 2020, 17, 543-558.	6.1	999
29	Age-Dependent Progression of SARS-CoV-2 Infection in Syrian Hamsters. Viruses, 2020, 12, 779.	1.5	192
30	Pathogenesis and transmission of SARS-CoV-2 in golden hamsters. Nature, 2020, 583, 834-838.	13.7	1,185
31	Immune-mediated approaches against COVID-19. Nature Nanotechnology, 2020, 15, 630-645.	15.6	260
32	Broad and Differential Animal Angiotensin-Converting Enzyme 2 Receptor Usage by SARS-CoV-2. Journal of Virology, 2020, 94, .	1.5	139
33	Lessons for COVID-19 Immunity from Other Coronavirus Infections. Immunity, 2020, 53, 248-263.	6.6	281
34	COVID-19 vaccine-readiness for anti-CD20-depleting therapy in autoimmune diseases. Clinical and Experimental Immunology, 2020, 202, 149-161.	1.1	155
35	Advances in the possible treatment of COVID-19: A review.. European Journal of Pharmacology, 2020, 883, 173372.	1.7	50
36	The epidemiology and therapeutic options for the COVID-19. Precision Clinical Medicine, 2020, 3, 71-84.	1.3	17

#	Article	IF	Citations
37	Increased expression of ACE2, the SARS-CoV-2 entry receptor, in alveolar and bronchial epithelium of smokers and COPD subjects. European Respiratory Journal, 2020, 56, 2002378.	3.1	67
38	Current Status of COVIDâ€19 (Pre)Clinical Vaccine Development. Angewandte Chemie - International Edition, 2020, 59, 18885-18897.	7.2	61
39	Infectivity, virulence, pathogenicity, host-pathogen interactions of SARS and SARS-CoV-2 in experimental animals: a systematic review. Veterinary Research Communications, 2020, 44, 101-110.	0.6	23
40	Severe acute respiratory syndrome coronavirusâ€2 natural animal reservoirs and experimental models: systematic review. Reviews in Medical Virology, 2021, 31, e2196.	3.9	24
41	STAT2 signaling restricts viral dissemination but drives severe pneumonia in SARS-CoV-2 infected hamsters. Nature Communications, 2020, 11, 5838.	5.8	225
42	Cardiovascular Manifestations of COVID-19 Infection. Cells, 2020, 9, 2508.	1.8	142
43	Longitudinal proteomic profiling reveals increased early inflammation and sustained apoptosis proteins in severe COVID-19. Scientific Reports, 2020, 10, 20533.	1.6	66
44	JAK-STAT Pathway Inhibition and their Implications in COVID-19 Therapy. Postgraduate Medicine, 2021, 133, 489-507.	0.9	110
45	RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response. Signal Transduction and Targeted Therapy, 2020, 5, 282.	7.1	149
46	Update on animal models for COVIDâ€19 research. British Journal of Pharmacology, 2020, 177, 5679-5681.	2.7	8
47	Investigation of COVID-19 comorbidities reveals genes and pathways coincident with the SARS-CoV-2 viral disease. Scientific Reports, 2020, 10, 20848.	1.6	32
48	Identifying the Zoonotic Origin of SARS-CoV-2 by Modeling the Binding Affinity between the Spike Receptor-Binding Domain and Host ACE2. Journal of Proteome Research, 2020, 19, 4844-4856.	1.8	27
49	A highly immunogenic and effective measles virus-based Th1-biased COVID-19 vaccine. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 32657-32666.	3.3	60
50	Lethality of SARS-CoV-2 infection in K18 human angiotensin-converting enzyme 2 transgenic mice. Nature Communications, 2020, 11, 6122.	5.8	304
51	Selection of animal models for COVID-19 research. VirusDisease, 2020, 31, 453-458.	1.0	24
52	The Interaction of Natural and Vaccine-Induced Immunity with Social Distancing Predicts the Evolution of the COVID-19 Pandemic. MBio, 2020, 11, .	1.8	23
53	I mmunosenescence and Inflammaging: Risk Factors of Severe COVID-19 in Older People. Frontiers in Immunology, 2020, 11, 579220.	2.2	115
54	Mouse-adapted SARS-CoV-2 replicates efficiently in the upper and lower respiratory tract of BALB/c and C57BL/6J mice. Protein and Cell, 2020, 11, 776-782.	4.8	77

#	Article	IF	Citations
56	Current Recommendations for the Management of Stroke Patients in the Middle East in the Era of COVID-19 Pandemic; Statement from the MENA SINO. Journal of Stroke and Cerebrovascular Diseases, 2020, 29, 105181.	0.7	6
57	A gendered magnifying glass on COVID-19. Clinical and Molecular Allergy, 2020, 18, 14.	0.8	19
58	Non-neuronal expression of SARS-CoV-2 entry genes in the olfactory system suggests mechanisms underlying COVID-19-associated anosmia. Science Advances, 2020, 6, .	4.7	865
59	The Long Road Toward COVID-19 Herd Immunity: Vaccine Platform Technologies and Mass Immunization Strategies. Frontiers in Immunology, 2020, 11, 1817.	2.2	189
60	Innate Immune Responses to Highly Pathogenic Coronaviruses and Other Significant Respiratory Viral Infections. Frontiers in Immunology, 2020, 11, 1979.	2.2	25
61	Deciphering the TCR Repertoire to Solve the COVID-19 Mystery. Trends in Pharmacological Sciences, 2020, 41, 518-530.	4.0	57
62	T cell responses in patients with COVID-19. Nature Reviews Immunology, 2020, 20, 529-536.	10.6	706
63	Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy. Science, 2020, 369, 1603-1607.	6.0	678
64	Classification of the present pharmaceutical agents based on the possible effective mechanism on the COVID-19 infection. DARU, Journal of Pharmaceutical Sciences, 2020, 28, 745-764.	0.9	14
65	Tumor markers as an entry for SARSâ€CoVâ€2 infection?. FEBS Journal, 2020, 287, 3677-3680.	2.2	25
66	Severe COVID-19 Is Marked by a Dysregulated Myeloid Cell Compartment. Cell, 2020, 182, 1419-1440.e23.	13.5	1,162
67	Replication-Competent Vesicular Stomatitis Virus Vaccine Vector Protects against SARS-CoV-2-Mediated Pathogenesis in Mice. Cell Host and Microbe, 2020, 28, 465-474.e4.	5.1	156
68	A Single Immunization with Nucleoside-Modified mRNA Vaccines Elicits Strong Cellular and Humoral Immune Responses against SARS-CoV-2 in Mice. Immunity, 2020, 53, 724-732.e7.	6.6	267
69	Potential role of ACE2 in coronavirus disease 2019 (COVID-19) prevention and management. Journal of Translational Internal Medicine, 2020, 8, 9-19.	1.0	105
70	Mapping Attenuation Determinants in Enterovirus-D68. Viruses, 2020, 12, 867.	1.5	4
71	Animal Models to Study Emerging Technologies Against SARS-CoV-2. Cellular and Molecular Bioengineering, 2020, 13, 293-303.	1.0	8
72	Transcriptomic analysis reveals novel mechanisms of SARSâ€CoVâ€2 infection in human lung cells. Immunity, Inflammation and Disease, 2020, 8, 753-762.	1.3	13
73	Vascular underpinning of COVID-19. Open Biology, 2020, 10, 200208.	1.5	22

#	Article	IF	Citations
74	Anti-COVID-19 drug screening: Frontier concepts and core technologies. Chinese Medicine, 2020, 15, 115.	1.6	8
75	Measuring immunity to SARS-CoV-2 infection: comparing assays and animal models. Nature Reviews Immunology, 2020, 20, 727-738.	10.6	107
76	Animal Models for COVID-19: More to the Picture Than ACE2, Rodents, Ferrets, and Non-human Primates. A Case for Porcine Respiratory Coronavirus and the Obese Ossabaw Pig. Frontiers in Microbiology, 2020, 11, 573756.	1.5	15
77	Mouse model of SARS-CoV-2 reveals inflammatory role of type I interferon signaling. Journal of Experimental Medicine, 2020, 217, .	4.2	357
78	Understanding the complexities of SARS-CoV2 infection and its immunology: A road to immune-based therapeutics. International Immunopharmacology, 2020, 88, 106980.	1.7	31
79	Genetically modified mouse models to help fight COVID-19. Nature Protocols, 2020, 15, 3777-3787.	5.5	26
80	High affinity binding of SARS-CoV-2 spike protein enhances ACE2 carboxypeptidase activity. Journal of Biological Chemistry, 2020, 295, 18579-18588.	1.6	82
81	Identification of a dominant CD8+ CTL epitope in the SARS-associated coronavirus 2 spike protein. Vaccine, 2020, 38, 7697-7701.	1.7	11
82	Animal models for SARSâ€CoVâ€2 research: A comprehensive literature review. Transboundary and Emerging Diseases, 2021, 68, 1868-1885.	1.3	58
83	Neutrophil extracellular traps infiltrate the lung airway, interstitial, and vascular compartments in severe COVID-19. Journal of Experimental Medicine, 2020, 217, .	4.2	274
84	Ocular conjunctival inoculation of SARS-CoV-2 can cause mild COVID-19 in rhesus macaques. Nature Communications, 2020, 11, 4400.	5.8	161
85	Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters. Nature Medicine, 2020, 26, 1694-1700.	15.2	275
86	A mouse model for SARS-CoV-2 infection by exogenous delivery of hACE2 using alphavirus replicon particles. Cell Research, 2020, 30, 1046-1048.	5.7	21
87	Potential Application of Drosophila melanogaster as a Model Organism in COVID-19-Related Research. Frontiers in Pharmacology, 2020, 11, 588561.	1.6	12
88	Immunological considerations for COVID-19 vaccine strategies. Nature Reviews Immunology, 2020, 20, 615-632.	10.6	806
89	Cell and animal models of SARS-CoV-2 pathogenesis and immunity. DMM Disease Models and Mechanisms, 2020, 13, .	1.2	46
90	Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Exhibits High Predicted Binding Affinity to ACE2 from Lagomorphs (Rabbits and Pikas). Animals, 2020, 10, 1460.	1.0	14
91	Structurally Resolved SARS-CoV-2 Antibody Shows High Efficacy in Severely Infected Hamsters and Provides a Potent Cocktail Pairing Strategy. Cell, 2020, 183, 1013-1023.e13.	13.5	227

#	Article	IF	Citations
92	SARS-CoV-2 Infection of Pluripotent Stem Cell-Derived Human Lung Alveolar Type 2 Cells Elicits a Rapid Epithelial-Intrinsic Inflammatory Response. Cell Stem Cell, 2020, 27, 962-973.e7.	5.2	266
93	Human Pluripotent Stem Cell-Derived Neural Cells and Brain Organoids Reveal SARS-CoV-2 Neurotropism Predominates in Choroid Plexus Epithelium. Cell Stem Cell, 2020, 27, 937-950.e9.	5.2	314
94	Detection of SARS-CoV-2 in a cat owned by a COVID-19â˜affected patient in Spain. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 24790-24793.	3.3	154
95	An overview of Middle East respiratory syndrome coronavirus vaccines in preclinical studies. Expert Review of Vaccines, 2020, 19, 817-829.	2.0	10
96	Of Mice and Men: The Coronavirus MHV and Mouse Models as a Translational Approach to Understand SARS-CoV-2. Viruses, 2020, 12, 880.	1.5	116
97	Friends or foes? The knowns and unknowns of natural killer cell biology in COVID-19 and other coronaviruses in July 2020. PLoS Pathogens, 2020, 16, e1008820.	2.1	21
98	Anosmia in COVID-19: Underlying Mechanisms and Assessment of an Olfactory Route to Brain Infection. Neuroscientist, 2021, 27, 582-603.	2.6	238
99	Coronavirus Antiviral Research Database (CoV-RDB): An Online Database Designed to Facilitate Comparisons between Candidate Anti-Coronavirus Compounds. Viruses, 2020, 12, 1006.	1.5	60
100	Prospects for mucosal vaccine: shutting the door on SARS-CoV-2. Human Vaccines and Immunotherapeutics, 2020, 16, 2921-2931.	1.4	85
101	<scp>SARSâ€CoV</scp>â€2 multifaceted interaction with the human host. Part <scp>II</scp>: Innate immunity response, immunopathology, and epigenetics. IUBMB Life, 2020, 72, 2331-2354.	1.5	29
102	SARS-CoV-2/COVID-19: Evolving Reality, Global Response, Knowledge Gaps, and Opportunities. Shock, 2020, 54, 416-437.	1.0	41
103	Vaccines for COVID-19. Clinical and Experimental Immunology, 2020, 202, 162-192.	1.1	185
104	SARS-CoV-2 spike produced in insect cells elicits high neutralization titres in non-human primates. Emerging Microbes and Infections, 2020, 9, 2076-2090.	3.0	53
105	Coronavirus disease 2019 (COVID-19) in domestic animals and wildlife: advances and prospects in the development of animal models for vaccine and therapeutic research. Human Vaccines and Immunotherapeutics, 2020, 16, 3043-3054.	1.4	26
106	The global response to the COVID-19 pandemic: how have immunology societies contributed?. Nature Reviews Immunology, 2020, 20, 594-602.	10.6	17
107	Severe acute respiratory syndrome coronavirus-2 and the deduction effect of angiotensin-converting enzyme 2 in pregnancy. Journal of the Chinese Medical Association, 2020, 83, 812-816.	0.6	14
108	Animal and translational models of SARS-CoV-2 infection and COVID-19. Mucosal Immunology, 2020, 13, 877-891.	2.7	155
109	Comparison of nonhuman primates identified the suitable model for COVID-19. Signal Transduction and Targeted Therapy, 2020, 5, 157.	7.1	190

#	Article	IF	Citations
110	Rethinking wastewater risks and monitoring in light of the COVID-19 pandemic. Nature Sustainability, 2020, 3, 981-990.	11.5	195
111	SARS-CoV-2 infection of human ACE2-transgenic mice causes severe lung inflammation and impaired function. Nature Immunology, 2020, 21, 1327-1335.	7.0	743
112	An Overview of SARS-CoV-2 and Animal Infection. Frontiers in Veterinary Science, 2020, 7, 596391.	0.9	117
113	Pathophysiology and potential future therapeutic targets using preclinical models of COVID-19. ERJ Open Research, 2020, 6, 00405-2020.	1.1	12
114	The Roborovski Dwarf Hamster Is A Highly Susceptible Model for a Rapid and Fatal Course of SARS-CoV-2 Infection. Cell Reports, 2020, 33, 108488.	2.9	76
115	Defining the Syrian hamster as a highly susceptible preclinical model for SARS-CoV-2 infection. Emerging Microbes and Infections, 2020, 9, 2673-2684.	3.0	193
116	Identification of Potent and Safe Antiviral Therapeutic Candidates Against SARS-CoV-2. Frontiers in Immunology, 2020, 11, 586572.	2.2	69
117	Host metabolism dysregulation and cell tropism identification in human airway and alveolar organoids upon SARS-CoV-2 infection. Protein and Cell, 2021, 12, 717-733.	4.8	75
118	Advances in Transgenic Mouse Models to Study Infections by Human Pathogenic Viruses. International Journal of Molecular Sciences, 2020, 21, 9289.	1.8	17
119	Coronavirus disease 2019: investigational therapies in the prevention and treatment of hyperinflammation. Expert Review of Clinical Immunology, 2020, 16, 1185-1204.	1.3	23
120	ADE and hyperinflammation in SARS-CoV2 infection- comparison with dengue hemorrhagic fever and feline infectious peritonitis. Cytokine, 2020, 136, 155256.	1.4	26
121	Challenges for Drug Repurposing in the COVID-19 Pandemic Era. Frontiers in Pharmacology, 2020, 11, 588654.	1.6	99
122	Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2): A Perspective Through the Lens of the Veterinary Diagnostic Laboratory. Frontiers in Veterinary Science, 2020, 7, 576267.	0.9	2
123	Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patientsâ€™ B Cells. Cell, 2020, 182, 73-84.e16.	13.5	1,139
124	Cross-reactive Antibody Response between SARS-CoV-2 and SARS-CoV Infections. Cell Reports, 2020, 31, 107725.	2.9	353
125	COVIDâ€19 vaccines: Knowing the unknown. European Journal of Immunology, 2020, 50, 939-943.	1.6	28
126	Animal models for emerging coronavirus: progress and new insights. Emerging Microbes and Infections, 2020, 9, 949-961.	3.0	50
127	A Critical Needs Assessment for Research in Companion Animals and Livestock Following the Pandemic of COVID-19 in Humans. Vector-Borne and Zoonotic Diseases, 2020, 20, 393-405.	0.6	70

#	Article	IF	Citations
128	In Vitro and Animal Models for SARS-CoV-2 research. Trends in Pharmacological Sciences, 2020, 41, 513-517.	4.0	154
129	Immunoregulation with mTOR inhibitors to prevent COVIDâ€19 severity: A novel intervention strategy beyond vaccines and specific antiviral medicines. Journal of Medical Virology, 2020, 92, 1495-1500.	2.5	79
130	Immunology of COVID-19: Current State of the Science. Immunity, 2020, 52, 910-941.	6.6	1,387
131	Role and mechanism of angiotensinâ€converting enzyme 2 in acute lung injury in coronavirus disease 2019. Chronic Diseases and Translational Medicine, 2020, 6, 98-105.	0.9	34
132	Pandemic Preparedness: Developing Vaccines and Therapeutic Antibodies For COVID-19. Cell, 2020, 181, 1458-1463.	13.5	92
133	A Mouse Model of SARS-CoV-2 Infection and Pathogenesis. Cell Host and Microbe, 2020, 28, 124-133.e4.	5.1	540
134	Mice with humanized-lungs and immune system - an idealized model for COVID-19 and other respiratory illness. Virulence, 2020, 11, 486-488.	1.8	10
135	Animal models of mechanisms of <scp>SARSâ€CoVâ€2</scp> infection and <scp>COVIDâ€19</scp> pathology. British Journal of Pharmacology, 2020, 177, 4851-4865.	2.7	158
136	COVID-19: molecular diagnostics overview. Journal of Molecular Medicine, 2020, 98, 947-954.	1.7	44
137	Response Letter: Radiation therapy for COVID-19 pneumopathy. Radiotherapy and Oncology, 2020, 149, 238-239.	0.3	3
138	Flattening the COVID-19 Curve With Natural Killer Cell Based Immunotherapies. Frontiers in Immunology, 2020, 11, 1512.	2.2	126
139	Role of Aging and the Immune Response to Respiratory Viral Infections: Potential Implications for COVID-19. Journal of Immunology, 2020, 205, 313-320.	0.4	60
140	The Modulation of Mucosal Antiviral Immunity by Immunobiotics: Could They Offer Any Benefit in the SARS-CoV-2 Pandemic?. Frontiers in Physiology, 2020, 11, 699.	1.3	50
141	Inhibition of Bruton tyrosine kinase in patients with severe COVID-19. Science Immunology, 2020, 5, .	5.6	304
142	The Lung Macrophage in SARS-CoV-2 Infection: A Friend or a Foe?. Frontiers in Immunology, 2020, 11, 1312.	2.2	143
143	Neuromechanisms of SARS-CoV-2: A Review. Frontiers in Neuroanatomy, 2020, 14, 37.	0.9	115
144	Cancer and SARS-CoV-2 Infection: Diagnostic and Therapeutic Challenges. Cancers, 2020, 12, 1581.	1.7	28
145	Severe COVID-19 and aging: are monocytes the key?. GeroScience, 2020, 42, 1051-1061.	2.1	118

#	Article	IF	Citations
146	Is hesperidin essential for prophylaxis and treatment of COVID-19 Infection?. Medical Hypotheses, 2020, 144, 109957.	0.8	90
147	Cytokine storm and leukocyte changes in mild versus severe SARS-CoV-2 infection: Review of 3939 COVID-19 patients in China and emerging pathogenesis and therapy concepts. Journal of Leukocyte Biology, 2020, 108, 17-41.	1.5	573
148	Generation of a Broadly Useful Model for COVID-19 Pathogenesis, Vaccination, and Treatment. Cell, 2020, 182, 734-743.e5.	13.5	398
149	A SARS-CoV-2 Infection Model in Mice Demonstrates Protection by Neutralizing Antibodies. Cell, 2020, 182, 744-753.e4.	13.5	486
150	Current global vaccine and drug efforts against COVID-19: Pros and cons of bypassing animal trials. Journal of Biosciences, 2020, 45, 1.	0.5	30
151	Hypothesis for the management and treatment of the COVID-19-induced acute respiratory distress syndrome and lung injury using mesenchymal stem cell-derived exosomes. Medical Hypotheses, 2020, 144, 109865.	0.8	46
152	Virology, Epidemiology, Pathogenesis, and Control of COVID-19. Viruses, 2020, 12, 372.	1.5	1,091
153	Drug targets for COVID-19 therapeutics: Ongoing global efforts. Journal of Biosciences, 2020, 45, 1.	0.5	69
154	COVID-19 Vaccines: â€œWarp Speedâ€•Needs Mind Melds, Not Warped Minds. Journal of Virology, 2020, 94, .	1.5	79
155	Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome. Blood, 2020, 136, 1169-1179.	0.6	1,071
156	SARS-CoV-2 Dissemination Through Peripheral Nerves Explains Multiple Organ Injury. Frontiers in Cellular Neuroscience, 2020, 14, 229.	1.8	64
157	SARS-CoV-2 pandemic and research gaps: Understanding SARS-CoV-2 interaction with the ACE2 receptor and implications for therapy. Theranostics, 2020, 10, 7448-7464.	4.6	180
158	A Comprehensive Review of Animal Models for Coronaviruses: SARS-CoV-2, SARS-CoV, and MERS-CoV. Virologica Sinica, 2020, 35, 290-304.	1.2	56
159	COVID-19 and the Chemical Senses: Supporting Players Take Center Stage. Neuron, 2020, 107, 219-233.	3.8	256
160	Primary exposure to SARS-CoV-2 protects against reinfection in rhesus macaques. Science, 2020, 369, 818-823.	6.0	416
161	Evidence for SARS-CoV-2 Infection of Animal Hosts. Pathogens, 2020, 9, 529.	1.2	167
162	Infection with novel coronavirus (SARS-CoV-2) causes pneumonia in Rhesus macaques. Cell Research, 2020, 30, 670-677.	5.7	194
163	Research progress on repositioning drugs and specific therapeutic drugs for SARS-CoV-2. Future Medicinal Chemistry, 2020, 12, 1565-1578.	1.1	22

#	Article	IF	Citations
164	The Potential of Various Nanotechnologies for Coronavirus Diagnosis/Treatment Highlighted through a Literature Analysis. Bioconjugate Chemistry, 2020, 31, 1873-1882.	1.8	41
165	Devilishly radical NETwork in COVID-19: Oxidative stress, neutrophil extracellular traps (NETs), and T cell suppression. Advances in Biological Regulation, 2020, 77, 100741.	1.4	172
166	COVIDâ€19: From pathogenesis models to the first drug trials. Microbial Biotechnology, 2020, 13, 1289-1299.	2.0	2
167	A Snapshot of the Global Race for Vaccines Targeting SARS-CoV-2 and the COVID-19 Pandemic. Frontiers in Pharmacology, 2020, 11, 937.	1.6	152
168	Neurobiology of coronaviruses: Potential relevance for COVID-19. Neurobiology of Disease, 2020, 143, 105007.	2.1	42
169	COVID-19: Progress in diagnostics, therapy and vaccination. Theranostics, 2020, 10, 7821-7835.	4.6	121
170	Commentary on two reports on animal models of COVIDâ€19. Animal Models and Experimental Medicine, 2020, 3, 115-116.	1.3	0
171	Is SARS-CoV-2 Also an Enteric Pathogen With Potential Fecalâ€"Oral Transmission? A COVID-19 Virological and Clinical Review. Gastroenterology, 2020, 159, 53-61.	0.6	157
172	Antibody therapies for the treatment of COVID-19. Antibody Therapeutics, 2020, 3, 101-108.	1.2	10
173	SARS-CoV-2 in wastewater: State of the knowledge and research needs. Science of the Total Environment, 2020, 739, 139076.	3.9	599
174	Does SARSâ€Covâ€2 invade the brain? Translational lessons from animal models. European Journal of Neurology, 2020, 27, 1764-1773.	1.7	214
175	Microstructure, pathophysiology, and potential therapeutics of COVIDâ€19: A comprehensive review. Journal of Medical Virology, 2021, 93, 275-299.	2.5	76
176	Fighting the War Against COVID-19 via Cell-Based Regenerative Medicine: Lessons Learned from 1918 Spanish Flu and Other Previous Pandemics. Stem Cell Reviews and Reports, 2021, 17, 9-32.	1.7	11
177	Risk factors for the COVIDâ€19 severity and its correlation with viral shedding: A retrospective cohort study. Journal of Medical Virology, 2021, 93, 952-961.	2.5	19
178	Advances in research on ACE2 as a receptor for 2019-nCoV. Cellular and Molecular Life Sciences, 2021, 78, 531-544.	2.4	87
179	First expert elicitation of knowledge on drivers of emergence of the COVIDâ€19 in pets. Transboundary and Emerging Diseases, 2021, 68, 626-636.	1.3	9
180	SARS-CoV-2 viability under different meteorological conditions, surfaces, fluids and transmission between animals. Environmental Research, 2021, 192, 110293.	3.7	20
181	Characteristics of SARS-CoV-2 and COVID-19. Nature Reviews Microbiology, 2021, 19, 141-154.	13.6	3,334

#	Article	IF	Citations
182	SARS-CoV-2 Induces a More Robust Innate Immune Response and Replicates Less Efficiently Than SARS-CoV in the Human Intestines: An ExÂVivo Study With Implications on Pathogenesis of COVID-19. Cellular and Molecular Gastroenterology and Hepatology, 2021, 11, 771-781.	2.3	41
183	Risk of humanâ€toâ€wildlife transmission of SARSâ€CoVâ€2. Mammal Review, 2021, 51, 272-292.	2.2	69
184	Lung Expression of Human Angiotensin-Converting Enzyme 2 Sensitizes the Mouse to SARS-CoV-2 Infection. American Journal of Respiratory Cell and Molecular Biology, 2021, 64, 79-88.	1.4	45
185	Assessing the consequences of environmental exposures on the expression of the human receptor and proteases involved in SARS-CoV-2 cell-entry. Environmental Research, 2021, 195, 110317.	3.7	11
186	Dalbavancin binds ACE2 to block its interaction with SARS-CoV-2 spike protein and is effective in inhibiting SARS-CoV-2 infection in animal models. Cell Research, 2021, 31, 17-24.	5.7	86
187	Hydroxychloroquine lung pharmacokinetics in critically ill patients with COVID-19. International Journal of Antimicrobial Agents, 2021, 57, 106247.	1.1	8
188	The Gastrointestinal Tract Is an Alternative Route for SARS-CoV-2 Infection in a Nonhuman Primate Model. Gastroenterology, 2021, 160, 1647-1661.	0.6	88
189	Rapid generation of ACE2 humanized inbred mouse model for COVID-19 with tetraploid complementation. National Science Review, 2021, 8, nwaa285.	4.6	19
190	Angiotensin-converting enzyme 2 and COVID-19: patients, comorbidities, and therapies. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2021, 320, L301-L330.	1.3	26
191	Establishment of an African green monkey model for COVID-19 and protection against re-infection. Nature Immunology, 2021, 22, 86-98.	7.0	162
192	Cellular mechanisms underlying neurological/neuropsychiatric manifestations of COVIDâ€19. Journal of Medical Virology, 2021, 93, 1983-1998.	2.5	38
193	COVID-19 treatments and pathogenesis including anosmia in K18-hACE2 mice. Nature, 2021, 589, 603-607.	13.7	394
194	Replication, pathogenicity, and transmission of SARS-CoV-2 in minks. National Science Review, 2021, 8, nwaa291.	4.6	72
195	Using Cardiovascular Cells from Human Pluripotent Stem Cells for COVID-19 Research: Why the Heart Fails. Stem Cell Reports, 2021, 16, 385-397.	2.3	25
196	COVID-19: The Effect of Host Genetic Variations on Hostâ€“Virus Interactions. Journal of Proteome Research, 2021, 20, 139-153.	1.8	14
197	Journey to a Receptor for Advanced Glycation End Products Connection in Severe Acute Respiratory Syndrome Coronavirus 2 Infection. Arteriosclerosis, Thrombosis, and Vascular Biology, 2021, 41, 614-627.	1.1	24
198	Identifying and repurposing antiviral drugs against severe acute respiratory syndrome coronavirus 2 with in silico and inÂvitro approaches. Biochemical and Biophysical Research Communications, 2021, 538, 137-144.	1.0	12
199	Sex-dependent immune response and lethality of COVID-19. Stem Cell Research, 2021, 50, 102116.	0.3	18

#	Article	IF	Citations
200	Commercialized diagnostic technologies to combat SARS-CoV2: Advantages and disadvantages. Talanta, 2021, 225, 121898.	2.9	43
201	SARS-CoV-2 vaccine candidates in rapid development. Human Vaccines and Immunotherapeutics, 2021, 17, 644-653.	1.4	30
202	Coronavirus biology and replication: implications for SARS-CoV-2. Nature Reviews Microbiology, 2021, 19, 155-170.	13.6	2,062
203	The comprehensive study on the therapeutic effects of baicalein for the treatment of COVID-19 in vivo and in vitro. Biochemical Pharmacology, 2021, 183, 114302.	2.0	98
204	Biomimetic Human Disease Model of SARSâ€CoVâ€2â€Induced Lung Injury and Immune Responses on Organ Chip System. Advanced Science, 2021, 8, 2002928.	5.6	119
205	Could SARS-CoV-2-induced lung injury be attenuated by vitamin D?. International Journal of Infectious Diseases, 2021, 102, 196-202.	1.5	20
206	Singleâ€cell RNA sequencing analysis of SARSâ€CoVâ€2 entry receptors in human organoids. Journal of Cellular Physiology, 2021, 236, 2950-2958.	2.0	19
207	Immunopathology of Hyperinflammation in COVID-19. American Journal of Pathology, 2021, 191, 4-17.	1.9	372
208	Leveraging on the genomics and immunopathology of SARS-CoV-2 for vaccines development: prospects and challenges. Human Vaccines and Immunotherapeutics, 2021, 17, 620-637.	1.4	3
209	SARSâ€CoVâ€2: Mechanism of infection and emerging technologies for future prospects. Reviews in Medical Virology, 2021, 31, e2168.	3.9	28
211	COVID 19-Induced Smell and Taste Impairments: Putative Impact on Physiology. Frontiers in Physiology, 2020, 11, 625110.	1.3	42
212	K18-hACE2 mice develop respiratory disease resembling severe COVID-19. PLoS Pathogens, 2021, 17, e1009195.	2.1	227
213	SARS-CoV-2 Causes a Systemically Multiple Organs Damages and Dissemination in Hamsters. Frontiers in Microbiology, 2020, 11, 618891.	1.5	46
214	A Potential Role of the Renin-Angiotensin-System for Disturbances of Respiratory Chemosensitivity in Acute Respiratory Distress Syndrome and Severe Acute Respiratory Syndrome. Frontiers in Physiology, 2020, 11, 588248.	1.3	6
215	Metabolic reprogramming and epigenetic changes of vital organs in SARS-CoV-2â€“induced systemic toxicity. JCI Insight, 2021, 6, .	2.3	57
216	COVID and Animal Trials: A Systematic Review. Journal of Pharmacy and Bioallied Sciences, 2021, 13, S31-S35.	0.2	4
217	Observations on the use of Brutonâ€™s tyrosine kinase inhibitors in SAR-CoV-2 and cancer. Journal of Hematology and Oncology, 2021, 14, 15.	6.9	6
218	SARS-CoV-2 in animals: From potential hosts to animal models. Advances in Virus Research, 2021, 110, 59-102.	0.9	33

#	Article	IF	Citations
219	COVID-19: angiotensin-converting enzyme 2 (ACE2) expression and tissue susceptibility to SARS-CoV-2 infection. European Journal of Clinical Microbiology and Infectious Diseases, 2021, 40, 905-919.	1.3	445
220	Nanog maintains stemness of Lkb1 â€deficient lung adenocarcinoma and prevents gastric differentiation. EMBO Molecular Medicine, 2021, 13, e12627.	3.3	5
221	ACE-2-interacting Domain of SARS-CoV-2 (AIDS) Peptide Suppresses Inflammation to Reduce Fever and Protect Lungs and Heart in Mice: Implications for COVID-19 Therapy. Journal of NeuroImmune Pharmacology, 2021, 16, 59-70.	2.1	33
222	Insights to SARS-CoV-2 life cycle, pathophysiology, and rationalized treatments that target COVID-19 clinical complications. Journal of Biomedical Science, 2021, 28, 9.	2.6	167
223	COVID-19 one year later: a retrospect of CRISPR-Cas system in combating COVID-19. International Journal of Biological Sciences, 2021, 17, 2080-2088.	2.6	6
224	Roborovski hamster (Phodopus roborovskii) strain SH101 as a systemic infection model of SARS-CoV-2. Virulence, 2021, 12, 2430-2442.	1.8	16
225	Antiviral activity of lambda-carrageenan against influenza viruses and severe acute respiratory syndrome coronavirus 2. Scientific Reports, 2021, 11, 821.	1.6	70
226	Vaccine Development and Immune Responses in COVID-19: Lessons from the Past. , 2021, , 149-185.		1
228	Predicting mammalian species at risk of being infected by SARS-CoV-2 from an ACE2 perspective. Scientific Reports, 2021, 11, 1702.	1.6	22
229	COVID-19 Pandemic and Vaccines. , 2021, , 205-235.		2
230	Understanding the Host Innate Immune Responses against SARS-CoV-2 Infection and COVID-19 Pathogenesis. Immune Network, 2021, 21, e1.	1.6	9
231	Similarities and differences between HIV and SARS-CoV-2. International Journal of Medical Sciences, 2021, 18, 846-851.	1.1	34
232	Bats, pangolins, minks and other animals - villains or victims of SARS-CoV-2?. Veterinary Research Communications, 2021, 45, 1-19.	0.6	41
233	Review of infective dose, routes of transmission and outcome of COVID-19 caused by the SARS-COV-2: comparison with other respiratory viruses. Epidemiology and Infection, 2021, 149, e96.	1.0	105
234	Disease severity-specific neutrophil signatures in blood transcriptomes stratify COVID-19 patients. Genome Medicine, 2021, 13, 7.	3.6	193
235	Role of vitamin D in regulating COVID-19 severityâ€"An immunological perspective. Journal of Leukocyte Biology, 2021, 110, 809-819.	1.5	17
236	A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein. Nature Communications, 2021, 12, 288.	5.8	224
238	Inhibitors of endosomal acidification suppress SARS-CoV-2 replication and relieve viral pneumonia in hACE2 transgenic mice. Virology Journal, 2021, 18, 46.	1.4	40

#	Article	IF	Citations
239	Immunopathological Changes in SARS-CoV-2 Critical and Non-critical Pneumonia Patients: A Systematic Review to Determine the Cause of Co-infection. Frontiers in Public Health, 2020, 8, 544993.	1.3	2
240	A single-dose mRNA vaccine provides a long-term protection for hACE2 transgenic mice from SARS-CoV-2. Nature Communications, 2021, 12, 776.	5.8	65
242	Can ACE2 Receptor Polymorphism Predict Species Susceptibility to SARS-CoV-2?. Frontiers in Public Health, 2020, 8, 608765.	1.3	35
243	A novel screening strategy of anti-SARS-CoV-2 drugs via blocking interaction between Spike RBD and ACE2. Environment International, 2021, 147, 106361.	4.8	10
244	Controversial Roles of the Renin Angiotensin System and Its Modulators During the COVID-19 Pandemic. Frontiers in Physiology, 2021, 12, 624052.	1.3	12
245	COVID-19 illness and autoimmune diseases: recent insights. Inflammation Research, 2021, 70, 407-428.	1.6	13
246	Experimental Models of SARS-CoV-2 Infection: Possible Platforms to Study COVID-19 Pathogenesis and Potential Treatments. Annual Review of Pharmacology and Toxicology, 2022, 62, 25-53.	4.2	20
247	Cyclic ⁶⁸Ga-Labeled Peptides for Specific Detection of Human Angiotensin-Converting Enzyme 2. Journal of Nuclear Medicine, 2021, 62, 1631-1637.	2.8	10
248	Restoration of SIRT3 gene expression by airway delivery resolves age-associated persistent lung fibrosis in mice. Nature Aging, 2021, 1, 205-217.	5.3	32
249	Induction of alarmin S100A8/A9 mediates activation of aberrant neutrophils in the pathogenesis of COVID-19. Cell Host and Microbe, 2021, 29, 222-235.e4.	5.1	145
250	Multi-organ proteomic landscape of COVID-19 autopsies. Cell, 2021, 184, 775-791.e14.	13.5	272
251	Post-exposure protection of SARS-CoV-2 lethal infected K18-hACE2 transgenic mice by neutralizing human monoclonal antibody. Nature Communications, 2021, 12, 944.	5.8	53
253	Susceptibility and Attenuated Transmissibility of SARS-CoV-2 in Domestic Cats. Journal of Infectious Diseases, 2021, 223, 1313-1321.	1.9	46
255	Inadvertent nucleotide sequence alterations during mutagenesis: highlighting the vulnerabilities in mouse transgenic technology. Journal of Genetic Engineering and Biotechnology, 2021, 19, 30.	1.5	3
256	Neutralizing antibody-dependent and -independent immune responses against SARS-CoV-2 in cynomolgus macaques. Virology, 2021, 554, 97-105.	1.1	30
257	SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801. Nature, 2021, 591, 451-457.	13.7	320
258	Potential intestinal infection and faecalâ€“oral transmission of SARS-CoV-2. Nature Reviews Gastroenterology and Hepatology, 2021, 18, 269-283.	8.2	223
259	Histone deacetylase inhibitors suppress ACE2 and ABO simultaneously, suggesting a preventive potential against COVID-19. Scientific Reports, 2021, 11, 3379.	1.6	36

#	Article	IF	Citations
260	In Vitro and In Vivo Models for Studying SARS-CoV-2, the Etiological Agent Responsible for COVID-19 Pandemic. Viruses, 2021, 13, 379.	1.5	53
261	SARS-CoV-2 spike D614G change enhances replication and transmission. Nature, 2021, 592, 122-127.	13.7	440
262	Estimating the Sensitivity of Fitted Parameters to Perturbations of Data with Calculus. Primus, 2022, 32, 168-198.	0.3	1
263	Development and deployment of COVID-19 vaccines for those most vulnerable. Science Translational Medicine, 2021, 13, .	5.8	60
264	Ebolavirus: Comparison of Survivor Immunology and Animal Models in the Search for a Correlate of Protection. Frontiers in Immunology, 2020, 11, 599568.	2.2	16
265	SARS-CoV-2 spike protein S1 subunit induces pro-inflammatory responses via toll-like receptor 4 signaling in murine and human macrophages. Heliyon, 2021, 7, e06187.	1.4	172
267	SARS-CoV-2 Infections in Animals: Reservoirs for Reverse Zoonosis and Models for Study. Viruses, 2021, 13, 494.	1.5	63
269	The Worldwide Search for the New Mutations in the RNA-Directed RNA Polymerase Domain of SARS-CoV-2. Macedonian Veterinary Review, 2021, 44, 87-94.	0.2	1
270	COVID-19 vasculitis and novel vasculitis mimics. Lancet Rheumatology, The, 2021, 3, e224-e233.	2.2	125
271	Nonsteroidal Anti-inflammatory Drugs Dampen the Cytokine and Antibody Response to SARS-CoV-2 Infection. Journal of Virology, 2021, 95, .	1.5	97
273	Neurotropic Effects of SARS-CoV-2 Modeled by the Human Brain Organoids. Stem Cell Reports, 2021, 16, 373-384.	2.3	43
274	SARSâ€CoVâ€2 infection aggravates chronic comorbidities of cardiovascular diseases and diabetes in mice. Animal Models and Experimental Medicine, 2021, 4, 2-15.	1.3	17
275	Insights into coronavirus immunity taught by the murine coronavirus. European Journal of Immunology, 2021, 51, 1062-1070.	1.6	14
276	Cytokine Drizzleâ€"The Rationale for Abandoning â€œCytokine Stormâ€• Shock, 2021, 56, 667-672.	1.0	20
277	Animal Hosts and Experimental Models of SARS-CoV-2 Infection. Chemotherapy, 2021, 66, 1-9.	0.8	13
278	Immune responses to SARS-CoV-2 infection in Humans and ACE2 humanized mice. Fundamental Research, 2021, 1, 124-130.	1.6	5
279	A Review of the Progress of COVID-19 Vaccine Development. Duzce Universitesi Tip FakÃ¼ltesi Dergisi, 2021, 23, 1-23.	0.3	7
280	Functional and genetic analysis of viral receptor ACE2 orthologs reveals a broad potential host range of SARS-CoV-2. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	168

#	Article	IF	Citations
281	Monitoring of SARSâ€CoVâ€2 infection in mustelids. EFSA Journal, 2021, 19, e06459.	0.9	60
282	SARS-CoV-2 spike protein binding selectively accelerates substrate-specific catalytic activity of ACE2. Journal of Biochemistry, 2021, 170, 299-306.	0.9	13
283	The risk from SARSâ€CoVâ€2 to bat species in england and mitigation options for conservation field workers. Transboundary and Emerging Diseases, 2022, 69, 694-705.	1.3	11
284	Protease-antiprotease imbalance in patients with severe COVID-19. Clinical Chemistry and Laboratory Medicine, 2021, 59, e330-e334.	1.4	19
285	Functional analysis of SARS-CoV-2 proteins in Drosophila identifies Orf6-induced pathogenic effects with Selinexor as an effective treatment. Cell and Bioscience, 2021, 11, 59.	2.1	18
286	The Impact of Angiotensin-Converting Enzyme 2 (ACE2) Expression on the Incidence and Severity of COVID-19 Infection. Pathogens, 2021, 10, 379.	1.2	16
287	Comparative analysis reveals the species-specific genetic determinants of ACE2 required for SARS-CoV-2 entry. PLoS Pathogens, 2021, 17, e1009392.	2.1	34
289	Single-cell meta-analysis of SARS-CoV-2 entry genes across tissues and demographics. Nature Medicine, 2021, 27, 546-559.	15.2	261
290	SARS-CoV-2 Exposure in Escaped Mink, Utah, USA. Emerging Infectious Diseases, 2021, 27, 988-990.	2.0	78
292	Light Sheet Microscopy-Assisted 3D Analysis of SARS-CoV-2 Infection in the Respiratory Tract of the Ferret Model. Viruses, 2021, 13, 529.	1.5	18
293	Mesenchymal Stem Cell-Derived Exosomes Exhibit Promising Potential for Treating SARS-CoV-2-Infected Patients. Cells, 2021, 10, 587.	1.8	34
294	Interactions of SARS-CoV-2 with the Bloodâ€“Brain Barrier. International Journal of Molecular Sciences, 2021, 22, 2681.	1.8	99
295	COVID-19 and Domestic Animals: Exploring the Species Barrier Crossing, Zoonotic and Reverse Zoonotic Transmission of SARS-CoV-2. Current Pharmaceutical Design, 2021, 27, 1194-1201.	0.9	16
297	Vaccine Development Against SARS-CoV-2: From Virology to Vaccine Clinical Trials. Coronaviruses, 2021, 2, 159-171.	0.2	4
299	COVID-19 and Pregnancy: Vertical Transmission and Inflammation Impact on Newborns. Vaccines, 2021, 9, 391.	2.1	22
301	Potential anti-COVID-19 agents, cepharanthine and nelfinavir, and their usage for combination treatment. IScience, 2021, 24, 102367.	1.9	126
302	A Comparison of Thrombosis and Hemorrhage Rates in Patients With Severe Respiratory Failure Due to Coronavirus Disease 2019 and Influenza Requiring Extracorporeal Membrane Oxygenation. Critical Care Medicine, 2021, 49, e663-e672.	0.4	40
303	Mefloquine, a Potent Anti-severe Acute Respiratory Syndrome-Related Coronavirus 2 (SARS-CoV-2) Drug as an Entry Inhibitor in vitro. Frontiers in Microbiology, 2021, 12, 651403.	1.5	25

#	Article	IF	Citations
304	Mink, SARS-CoV-2, and the Human-Animal Interface. Frontiers in Microbiology, 2021, 12, 663815.	1.5	106
305	Vasculitis and Neutrophil Extracellular Traps in Lungs of Golden Syrian Hamsters With SARS-CoV-2. Frontiers in Immunology, 2021, 12, 640842.	2.2	45
306	Critical ACE2 Determinants of SARS-CoV-2 and Group 2B Coronavirus Infection and Replication. MBio, 2021, 12, .	1.8	8
307	Novel transgenic mice with Cre-dependent co-expression of GFP and human ACE2: a safe tool for study of COVID-19 pathogenesis. Transgenic Research, 2021, 30, 289-301.	1.3	10
308	A Nanoscaffolded Spike-RBD Vaccine Provides Protection against SARS-CoV-2 with Minimal Anti-Scaffold Response. Vaccines, 2021, 9, 431.	2.1	18
309	SARS-CoV-2 Infects Human EngineeredÂHeart Tissues and Models COVID-19 Myocarditis. JACC Basic To Translational Science, 2021, 6, 331-345.	1.9	121
310	Bridging animal and clinical research during SARS-CoV-2 pandemic: A new-old challenge. EBioMedicine, 2021, 66, 103291.	2.7	15
311	Animal Models of COVID-19 II. Comparative Immunology. ILAR Journal, 2021, 62, 17-34.	1.8	20
312	Exposure to particulate matter upregulates ACE2 and TMPRSS2 expression in the murine lung. Environmental Research, 2021, 195, 110722.	3.7	37
313	SARS-CoV-2 Entry Inhibitors Targeting Virus-ACE2 or Virus-TMPRSS2 Interactions. Current Medicinal Chemistry, 2022, 29, 682-699.	1.2	5
314	Intranasal versus intratracheal exposure to lipopolysaccharides in a murine model of acute respiratory distress syndrome. Scientific Reports, 2021, 11, 7777.	1.6	22
315	BNT162b2 Vaccine Encoding the SARS-CoV-2 P2 S Protects Transgenic hACE2 Mice against COVID-19. Vaccines, 2021, 9, 324.	2.1	14
316	Current Status of Putative Animal Sources of SARS-CoV-2 Infection in Humans: Wildlife, Domestic Animals and Pets. Microorganisms, 2021, 9, 868.	1.6	38
317	SARS-CoV-2: Pathogenesis, Molecular Targets and Experimental Models. Frontiers in Pharmacology, 2021, 12, 638334.	1.6	14
318	The olfactory nerve is not a likely route to brain infection in COVID-19: a critical review of data from humans and animal models. Acta Neuropathologica, 2021, 141, 809-822.	3.9	94
319	In Vitro Lung Models and Their Application to Study SARS-CoV-2 Pathogenesis and Disease. Viruses, 2021, 13, 792.	1.5	30
320	SARS-CoV-2 transmission via aquatic food animal species or their products: A review. Aquaculture, 2021, 536, 736460.	1.7	30
321	SARS-CoV-2 mediated neuroinflammation and the impact of COVID-19 in neurological disorders. Cytokine and Growth Factor Reviews, 2021, 58, 1-15.	3.2	84

#	Article	IF	Citations
322	Sex Differences in the Induction of Angiotensin Converting Enzyme 2 (Ace-2) in Mouse Lungs after E-Cigarette Vapor Exposure and Its Relevance to Covid-19. Journal of Investigative Medicine, 2021, 69, 954-961.	0.7	14
323	Recombinant Human Thymosin Beta-4 Protects against Mouse Coronavirus Infection. Mediators of Inflammation, 2021, 2021, 1-9.	1.4	5
324	Infectious Clones Produce SARS-CoV-2 That Causes Severe Pulmonary Disease in Infected K18-Human ACE2 Mice. MBio, 2021, 12, .	1.8	9
325	Distinct uptake, amplification, and release of SARS-CoV-2 by M1 and M2 alveolar macrophages. Cell Discovery, 2021, 7, 24.	3.1	91
326	The Mechanisms and Animal Models of SARS-CoV-2 Infection. Frontiers in Cell and Developmental Biology, 2021, 9, 578825.	1.8	20
327	Cell-Type Apoptosis in Lung during SARS-CoV-2 Infection. Pathogens, 2021, 10, 509.	1.2	47
329	Human-Based Advanced in vitro Approaches to Investigate Lung Fibrosis and Pulmonary Effects of COVID-19. Frontiers in Medicine, 2021, 8, 644678.	1.2	31
331	Comparative analyses of ACE2 and TMPRSS2 gene: Implications for the risk to which vertebrate animals are susceptible to SARSâ€CoVâ€2. Journal of Medical Virology, 2021, 93, 5487-5504.	2.5	11
333	TOP1 inhibition therapy protects against SARS-CoV-2-induced lethal inflammation. Cell, 2021, 184, 2618-2632.e17.	13.5	80
334	Human convalescent plasma protects K18-hACE2 mice against severe respiratory disease. Journal of General Virology, 2021, 102, .	1.3	6
335	Susceptibility of White-Tailed Deer (Odocoileus virginianus) to SARS-CoV-2. Journal of Virology, 2021, 95, .	1.5	192
336	Latest updates on SARS-CoV-2 genomic characterization, drug, and vaccine development; a comprehensive bioinformatics review. Microbial Pathogenesis, 2021, 154, 104809.	1.3	4
338	SARS-CoV-2 Rapidly Adapts in Aged BALB/c Mice and Induces Typical Pneumonia. Journal of Virology, 2021, 95, .	1.5	43
339	A diamidobenzimidazole STING agonist protects against SARS-CoV-2 infection. Science Immunology, 2021, 6, .	5.6	96
340	Relating Ventilatory Support and Drug Treatment Strategies to the Fundamental Pathophysiology in COVID-19 Illness. European Medical Journal (Chelmsford, England), 0, , .	3.0	0
344	Q493K and Q498H substitutions in Spike promote adaptation of SARS-CoV-2 in mice. EBioMedicine, 2021, 67, 103381.	2.7	102
345	The interferon-stimulated exosomal hACE2 potently inhibits SARS-CoV-2 replication through competitively blocking the virus entry. Signal Transduction and Targeted Therapy, 2021, 6, 189.	7.1	26
346	SARS-CoV-2 infection, neuropathogenesis and transmission among deer mice: Implications for spillback to New World rodents. PLoS Pathogens, 2021, 17, e1009585.	2.1	96

#	Article	IF	Citations
348	Sequential infection with H1N1 and SARS-CoV-2 aggravated COVID-19 pathogenesis in a mammalian model, and co-vaccination as an effective method of prevention of COVID-19 and influenza. Signal Transduction and Targeted Therapy, 2021, 6, 200.	7.1	41
350	Local Sustained GM-CSF Delivery by Genetically Engineered Encapsulated Cells Enhanced Both Cellular and Humoral SARS-CoV-2 Spike-Specific Immune Response in an Experimental Murine Spike DNA Vaccination Model. Vaccines, 2021, 9, 484.	2.1	5
351	Stem cell therapies and benefaction of somatic cell nuclear transfer cloning in COVID-19 era. Stem Cell Research and Therapy, 2021, 12, 283.	2.4	11
352	Human pluripotent stem cell-based organoids and cell platforms for modelling SARS-CoV-2 infection and drug discovery. Stem Cell Research, 2021, 53, 102207.	0.3	13
354	Drug combination therapy for emerging viral diseases. Drug Discovery Today, 2021, 26, 2367-2376.	3.2	65
356	On the road to ending the COVID-19 pandemic: Are we there yet?. Virology, 2021, 557, 70-85.	1.1	38
357	A cohort autopsy study defines COVID-19 systemic pathogenesis. Cell Research, 2021, 31, 836-846.	5.7	93
358	SARS-CoV-2 infection and transmission in the North American deer mouse. Nature Communications, 2021, 12, 3612.	5.8	96
359	A Retrospective Assessment of the Initial Phase of Covid-19 and Its Implemented Treatment Strategies. Journal of Drug Delivery and Therapeutics, 2021, 11, 81-89.	0.2	0
360	Human Defensins Inhibit SARS-CoV-2 Infection by Blocking Viral Entry. Viruses, 2021, 13, 1246.	1.5	35
361	Drosophila, a powerful model to study virus-host interactions and pathogenicity in the fight against SARS-CoV-2. Cell and Bioscience, 2021, 11, 110.	2.1	12
362	A Review of Neurological Involvement in Patients with SARS-CoV-2 Infection. Medical Science Monitor, 2021, 27, e932962.	0.5	11
364	Key Considerations for the Development of Safe and Effective SARSâ€CoVâ€2 Subunit Vaccine: A Peptideâ€Based Vaccine Alternative. Advanced Science, 2021, 8, e2100985.	5.6	16
368	The Fc-mediated effector functions of a potent SARS-CoV-2 neutralizing antibody, SC31, isolated from an early convalescent COVID-19 patient, are essential for the optimal therapeutic efficacy of the antibody. PLoS ONE, 2021, 16, e0253487.	1.1	76
369	Surface Proteins of SARS-CoV-2 Drive Airway Epithelial Cells to Induce IFN-Dependent Inflammation. Journal of Immunology, 2021, 206, 3000-3009.	0.4	8
370	Defense of COVID-19 by Human Organoids. Phenomics, 2021, 1, 113-128.	0.9	8
372	In silico comparison of SARS-CoV-2 spike protein-ACE2 binding affinities across species and implications for virus origin. Scientific Reports, 2021, 11, 13063.	1.6	77
374	Animal models for SARS-CoV-2. Current Opinion in Virology, 2021, 48, 73-81.	2.6	52

#	Article	IF	Citations
375	Relating Ventilatory Support and Drug Treatment Strategies to the Fundamental Pathophysiology in COVID-19 Illness. European Medical Journal (Chelmsford, England), 0, , .	3.0	0
376	Experimental Models for SARS-CoV-2 Infection. Molecules and Cells, 2021, 44, 377-383.	1.0	6
378	Towards Goals to Refine Prophylactic and Therapeutic Strategies Against COVID-19 Linked to Aging and Metabolic Syndrome. Cells, 2021, 10, 1412.	1.8	6
380	Animal models for SARS-Cov2/Covid19 research-A commentary. Biochemical Pharmacology, 2021, 188, 114543.	2.0	14
381	Mice with induced pulmonary morbidities display severe lung inflammation and mortality following exposure to SARS-CoV-2. JCI Insight, 2021, 6, .	2.3	7
382	Transmission and Protection against Reinfection in the Ferret Model with the SARS-CoV-2 USA-WA1/2020 Reference Isolate. Journal of Virology, 2021, 95, e0223220.	1.5	25
383	Tofacitinib therapy intercepts macrophage metabolic reprogramming instigated by SARSâ€CoVâ€2 Spike protein. European Journal of Immunology, 2021, 51, 2330-2340.	1.6	16
384	Rapid, reliable, and reproducible cell fusion assay to quantify SARS-Cov-2 spike interaction with hACE2. PLoS Pathogens, 2021, 17, e1009683.	2.1	18
385	SARS-CoV-2 envelope protein causes acute respiratory distress syndrome (ARDS)-like pathological damages and constitutes an antiviral target. Cell Research, 2021, 31, 847-860.	5.7	102
386	Molecular evidence suggesting the persistence of residual SARSâ€CoVâ€2 and immune responses in the placentas of pregnant patients recovered from COVIDâ€19. Cell Proliferation, 2021, 54, e13091.	2.4	12
387	A computational study of the interface interaction between SARSâ€CoVâ€2 RBD and ACE2 from human, cat, dog, and ferret. Transboundary and Emerging Diseases, 2022, 69, 2287-2295.	1.3	4
389	Animal Transmission of SARS-CoV-2 and the Welfare of Animals during the COVID-19 Pandemic. Animals, 2021, 11, 2044.	1.0	9
390	Glycosylation of SARS-CoV-2: structural and functional insights. Analytical and Bioanalytical Chemistry, 2021, 413, 7179-7193.	1.9	56
392	A novel mouse AAV6 hACE2 transduction model of wild-type SARS-CoV-2 infection studied using synDNA immunogens. IScience, 2021, 24, 102699.	1.9	15
393	One Year of the COVIDâ€19 Pandemic. What Do We Know and What Is Yet to Come? â€" The Summarising Review. International Journal of Public Health, 2021, 66, 1603975.	1.0	3
394	Metformin inhibition of mitochondrial ATP and DNA synthesis abrogates NLRP3 inflammasome activation and pulmonary inflammation. Immunity, 2021, 54, 1463-1477.e11.	6.6	179
395	A single dose of replication-competent VSV-vectored vaccine expressing SARS-CoV-2 S1 protects against virus replication in a hamster model of severe COVID-19. Npj Vaccines, 2021, 6, 91.	2.9	19
396	ACE2-lentiviral transduction enables mouse SARS-CoV-2 infection and mapping of receptor interactions. PLoS Pathogens, 2021, 17, e1009723.	2.1	28

#	Article	IF	Citations
397	Implementation of Adenovirus-Mediated Pulmonary Expression of Human ACE2 in HLA Transgenic Mice Enables Establishment of a COVID-19 Murine Model for Assessment of Immune Responses to SARS-CoV-2 Infection. Pathogens, 2021, 10, 940.	1.2	1
398	Pathophysiology of COVID-19-associated acute kidney injury. Nature Reviews Nephrology, 2021, 17, 751-764.	4.1	280
399	Combination of a Sindbis-SARS-CoV-2 Spike Vaccine and Î±OX40 Antibody Elicits Protective Immunity Against SARS-CoV-2 Induced Disease and Potentiates Long-Term SARS-CoV-2-Specific Humoral and T-Cell Immunity. Frontiers in Immunology, 2021, 12, 719077.	2.2	9
400	Rabbit Monoclonal Antibody Specifically Recognizing a Linear Epitope in the RBD of SARS-CoV-2 Spike Protein. Vaccines, 2021, 9, 829.	2.1	9
401	Mutants of human ACE2 differentially promote SARS-CoV and SARS-CoV-2 spike mediated infection. PLoS Pathogens, 2021, 17, e1009715.	2.1	24
402	Cancer and COVID-19: Why are cancer patients more susceptible to COVID-19?. Medical Oncology, 2021, 38, 101.	1.2	31
403	Intranasal Administration of a Monoclonal Neutralizing Antibody Protects Mice against SARS-CoV-2 Infection. Viruses, 2021, 13, 1498.	1.5	33
404	Non-human primate models of human respiratory infections. Molecular Immunology, 2021, 135, 147-164.	1.0	17
405	Mechanistic understanding of innate and adaptive immune responses in SARS-CoV-2 infection. Molecular Immunology, 2021, 135, 268-275.	1.0	15
406	Structural and functional basis for pan-CoV fusion inhibitors against SARS-CoV-2 and its variants with preclinical evaluation. Signal Transduction and Targeted Therapy, 2021, 6, 288.	7.1	38
407	Postinfection treatment with a protease inhibitor increases survival of mice with a fatal SARS-CoV-2 infection. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	61
408	Age-dependent appearance of SARS-CoV-2 entry sites in mouse chemosensory systems reflects COVID-19 anosmia-ageusia symptoms. Communications Biology, 2021, 4, 880.	2.0	10
409	Image processing unravels the evolutionary pattern of SARS-CoV-2 against SARS and MERS through position-based pattern recognition. Computers in Biology and Medicine, 2021, 134, 104471.	3.9	2
410	The pig as a medical model for acquired respiratory diseases and dysfunctions: An immunological perspective. Molecular Immunology, 2021, 135, 254-267.	1.0	18
411	3D Bioprinting for fabrication of tissue models of COVID-19 infection. Essays in Biochemistry, 2021, 65, 503-518.	2.1	11
412	Animal reservoirs of SARS-CoV-2: calculable COVID-19 risk for older adults from animal to human transmission. GeroScience, 2021, 43, 2305-2320.	2.1	15
413	Therapeutic potential of mesenchymal stem cells in multiple organs affected by COVID-19. Life Sciences, 2021, 278, 119510.	2.0	8
414	The potential use of Drosophila as an in vivo model organism for COVID-19-related research: a review. Turkish Journal of Biology, 2021, 45, 559-569.	2.1	4

#	Article	IF	Citations
415	The SARS-CoV-2 spike protein subunit S1 induces COVID-19-like acute lung injury in Îš18-hACE2 transgenic mice and barrier dysfunction in human endothelial cells. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2021, 321, L477-L484.	1.3	82
416	Neurological manifestations of COVID-19 in patients: from path physiology to therapy. Neurological Sciences, 2021, 42, 4867-4879.	0.9	9
417	Highly susceptible SARS-CoV-2 model in CAG promoterâ€“driven hACE2-transgenic mice. JCI Insight, 2021, 6, .	2.3	21
419	Characterization of Virus Replication, Pathogenesis, and Cytokine Responses in Syrian Hamsters Inoculated with SARS-CoV-2. Journal of Inflammation Research, 2021, Volume 14, 3781-3795.	1.6	13
420	Multi-Organ Histopathological Changes in a Mouse Hepatitis Virus Model of COVID-19. Viruses, 2021, 13, 1703.	1.5	13
421	Challenges and Progress in Vaccine Development for COVID-19 Coronavirus (SARS-CoV-2): A Review. The Open Covid Journal, 2021, 1, 65-76.	0.4	0
422	Human Stem Cell Models of SARS-CoV-2 Infection in the Cardiovascular System. Stem Cell Reviews and Reports, 2021, 17, 2107-2119.	1.7	0
423	Rapid generation of mouse model for emerging infectious disease with the case of severe COVID-19. PLoS Pathogens, 2021, 17, e1009758.	2.1	17
424	Animal Models for COVID-19: Hamsters, Mouse, Ferret, Mink, Tree Shrew, and Non-human Primates. Frontiers in Microbiology, 2021, 12, 626553.	1.5	90
425	Protective Effects of Astodrimer Sodium 1% Nasal Spray Formulation against SARS-CoV-2 Nasal Challenge in K18-hACE2 Mice. Viruses, 2021, 13, 1656.	1.5	14
426	A highly potent and stable pan-coronavirus fusion inhibitor as a candidate prophylactic and therapeutic for COVID-19 and other coronavirus diseases. Acta Pharmaceutica Sinica B, 2022, 12, 1652-1661.	5.7	24
428	Potential SARS-CoV-2 vaccines: Concept, progress, and challenges. International Immunopharmacology, 2021, 97, 107622.	1.7	14
429	Induction of interferon response by high viral loads at early stage infection may protect against severe outcomes in COVID-19 patients. Scientific Reports, 2021, 11, 15715.	1.6	15
430	Establishment of a humanized swine model for COVID-19. Cell Discovery, 2021, 7, 70.	3.1	5
431	A mouse model of lethal respiratory dysfunction for SARS-CoV-2 infection. Antiviral Research, 2021, 193, 105138.	1.9	14
432	Biology and Pathogenesis of SARS-CoV-2: Understandings for Therapeutic Developments against COVID-19. Pathogens, 2021, 10, 1218.	1.2	4
433	Analysis of Intermediate Hosts and Susceptible Animals of SARS-CoV-2 by Computational Methods. Zoonoses, 2021, 1, .	0.5	4
434	A Biosafety Level 2 Mouse Model for Studying Betacoronavirus-Induced Acute Lung Damage and Systemic Manifestations. Journal of Virology, 2021, 95, e0127621.	1.5	23

#	Article	IF	Citations
435	Resveratrol as an Adjunctive Therapy for Excessive Oxidative Stress in Aging COVID-19 Patients. Antioxidants, 2021, 10, 1440.	2.2	28
437	Interleukin-1RA Mitigates SARS-CoV-2â€“Induced Inflammatory Lung Vascular Leakage and Mortality in Humanized K18-hACE-2 Mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 2021, 41, 2773-2785.	1.1	20
438	Sequences in the cytoplasmic tail of SARS-CoV-2 Spike facilitate expression at the cell surface and syncytia formation. Nature Communications, 2021, 12, 5333.	5.8	64
439	Critical Update on the Diagnosis and Management of COVID-19 in Advanced Cirrhosis and Liver Transplant Recipients. Journal of Clinical and Translational Hepatology, 2021, 000, 000-000.	0.7	3
440	Bruton tyrosine kinase inhibitors as potential therapeutic agents for COVID-19: A review. Metabolism Open, 2021, 11, 100116.	1.4	12
441	Zoonotic and anthropozoonotic potential of COVID-19 and its implications for public health. Environmental Science and Pollution Research, 2021, 28, 52599-52609.	2.7	4
442	Cellular host factors for SARS-CoV-2 infection. Nature Microbiology, 2021, 6, 1219-1232.	5.9	127
443	Trend and prediction of COVID-19 outbreak in Iran: SEIR and ANFIS model. Polish Journal of Medical Physics and Engineering, 2021, 27, 241-249.	0.2	2
444	Combining spike- and nucleocapsid-based vaccines improves distal control of SARS-CoV-2. Cell Reports, 2021, 36, 109664.	2.9	99
445	SARS-CoV-2 crosses the bloodâ€“brain barrier accompanied with basement membrane disruption without tight junctions alteration. Signal Transduction and Targeted Therapy, 2021, 6, 337.	7.1	157
446	Characterization and structural basis of a lethal mouse-adapted SARS-CoV-2. Nature Communications, 2021, 12, 5654.	5.8	89
447	The nucleoside antiviral prodrug remdesivir in treating COVID-19 and beyond with interspecies significance. Animal Diseases, 2021, 1, 15.	0.6	4
448	Protective Efficacy of Rhesus Adenovirus COVID-19 Vaccines against Mouse-Adapted SARS-CoV-2. Journal of Virology, 2021, 95, e0097421.	1.5	12
449	Potential biomarkers for the early prediction of SARS-COV-2 disease outcome. Microbial Pathogenesis, 2021, 158, 105057.	1.3	18
450	Neuropsychiatric Disorders and COVID-19: What We Know So Far. Pharmaceuticals, 2021, 14, 933.	1.7	10
451	Transient acquisition of cross-species infectivity during the evolution of SARS-CoV-2. National Science Review, 2021, 8, nwab167.	4.6	17
452	The origins of SARS-CoV-2: A critical review. Cell, 2021, 184, 4848-4856.	13.5	330
454	COVID-19 Animal Models and Vaccines: Current Landscape and Future Prospects. Vaccines, 2021, 9, 1082.	2.1	8

#	Article	IF	Citations
455	The COVID-19 Global Pandemic and Its Impact on the Mental Health of Nurses in Malaysia. Healthcare (Switzerland), 2021, 9, 1259.	1.0	9
456	Inhibition of Autophagy Suppresses SARS-CoV-2 Replication and Ameliorates Pneumonia in hACE2 Transgenic Mice and Xenografted Human Lung Tissues. Journal of Virology, 2021, 95, e0153721.	1.5	38
457	Neurological manifestations of COVID-19: A comprehensive literature review and discussion of mechanisms. Journal of Neuroimmunology, 2021, 358, 577658.	1.1	52
458	Repurpose but also (nano)-reformulate! The potential role of nanomedicine in the battle against SARS-CoV2. Journal of Controlled Release, 2021, 337, 258-284.	4.8	12
459	Therapeutic potential of melatonin and melatonergic drugs on K18â€‹hACE2 mice infected with SARSâ€CoVâ€‹2. Journal of Pineal Research, 2022, 72, e12772.	3.4	20
462	The mechanisms and clinical application of Traditional Chinese Medicine Lianhua-Qingwen capsule. Biomedicine and Pharmacotherapy, 2021, 142, 111998.	2.5	39
463	Ion therapy of pulmonary fibrosis by inhalation of ionic solution derived from silicate bioceramics. Bioactive Materials, 2021, 6, 3194-3206.	8.6	15
464	Coronaviruses, cholesterol and statins: Involvement and application for Covid-19. Biochimie, 2021, 189, 51-64.	1.3	11
465	Immune response to COVID-19 in older adults. Journal of Heart and Lung Transplantation, 2021, 40, 1082-1089.	0.3	13
466	Adenovirus transduction to express human ACE2 causes obesity-specific morbidity in mice, impeding studies on the effect of host nutritional status on SARS-CoV-2 pathogenesis. Virology, 2021, 563, 98-106.	1.1	6
467	In Vivo protection from SARS-CoV-2 infection by ATN-161 in k18-hACE2 transgenic mice. Life Sciences, 2021, 284, 119881.	2.0	22
468	Evaluation of a multi-species SARS-CoV-2 surrogate virus neutralization test. One Health, 2021, 13, 100313.	1.5	28
469	SARS-CoV-2 spike promotes inflammation and apoptosis through autophagy by ROS-suppressed PI3K/AKT/mTOR signaling. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2021, 1867, 166260.	1.8	102
470	Drug repurposing for COVID-19: Approaches, challenges and promising candidates. , 2021, 228, 107930.		85
471	Animal models of SARS-CoV-2 and COVID-19 for the development of prophylactic and therapeutic interventions. , 2021, 228, 107931.		18
472	SARS-CoV-2 RNA concentrations in wastewater foreshadow dynamics and clinical presentation of new COVID-19 cases. Science of the Total Environment, 2022, 805, 150121.	3.9	192
473	Serum Amyloid P inhibits single stranded RNA-induced lung inflammation, lung damage, and cytokine storm in mice. PLoS ONE, 2021, 16, e0245924.	1.1	9
474	SARS-CoV-2 infection in K18-ACE2 transgenic mice replicates human pulmonary disease in COVID-19. Cellular and Molecular Immunology, 2021, 18, 513-514.	4.8	42

#	Article	IF	Citations
475	Experimental Animal Models of Coronavirus Infections: Strengths and Limitations. Immune Network, 2021, 21, e12.	1.6	12
476	A mouse model for SARS-CoV-2-induced acute respiratory distress syndrome. Signal Transduction and Targeted Therapy, 2021, 6, 1.	7.1	558
477	Hamsters as a Model of Severe Acute Respiratory Syndrome Coronavirus-2. Comparative Medicine, 2021, 71, 398-410.	0.4	13
478	Monocytes and Macrophages, Targets of Severe Acute Respiratory Syndrome Coronavirus 2: The Clue for Coronavirus Disease 2019 Immunoparalysis. Journal of Infectious Diseases, 2021, 224, 395-406.	1.9	141
479	H1N1 exposure during the convalescent stage of SARS-CoV-2 infection results in enhanced lung pathologic damage in hACE2 transgenic mice. Emerging Microbes and Infections, 2021, 10, 1156-1168.	3.0	6
480	Immunological perspectives on the pathogenesis, diagnosis, prevention and treatment of COVID-19. Molecular Biomedicine, 2021, 2, 1.	1.7	20
482	Potent mouse monoclonal antibodies that block SARS-CoV-2 infection. Journal of Biological Chemistry, 2021, 296, 100346.	1.6	15
483	Lessons learned 1 year after SARS-CoV-2 emergence leading to COVID-19 pandemic. Emerging Microbes and Infections, 2021, 10, 507-535.	3.0	202
484	Sensitivity of SARSâ€CoVâ€2 to different temperatures. Animal Models and Experimental Medicine, 2020, 3, 316-318.	1.3	10
485	ACTIVating Resources for the COVID-19 Pandemic: InÂVivo Models for Vaccines and Therapeutics. Cell Host and Microbe, 2020, 28, 646-659.	5.1	36
486	Overview of the current promising approaches for the development of an effective severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine. International Immunopharmacology, 2020, 88, 106928.	1.7	25
487	Spiking Pandemic Potential: Structural and Immunological Aspects of SARS-CoV-2. Trends in Microbiology, 2020, 28, 605-618.	3.5	28
488	Consensus summary report for CEPI/BC March 12â€“13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines. Vaccine, 2020, 38, 4783-4791.	1.7	102
489	Characterization of the SARS-CoV-2 S Protein: Biophysical, Biochemical, Structural, and Antigenic Analysis. ACS Omega, 2021, 6, 85-102.	1.6	54
490	Development of immunohistochemistry and in situ hybridisation for the detection of SARS-CoV and SARS-CoV-2 in formalin-fixed paraffin-embedded specimens. Scientific Reports, 2020, 10, 21894.	1.6	18
491	Transmission and prevention of SARS-CoV-2. Biochemical Society Transactions, 2020, 48, 2307-2316.	1.6	35
492	Key residues influencing binding affinities of 2019-nCoV with ACE2 in different species. Briefings in Bioinformatics, 2021, 22, 963-975.	3.2	14
493	Transmission of Severe Acute Respiratory Syndrome Coronavirus 2 via Close Contact and Respiratory Droplets Among Human Angiotensin-Converting Enzyme 2 Mice. Journal of Infectious Diseases, 2020, 222, 551-555.	1.9	61

#	Article	IF	Citations
542	Biological Mechanisms of COVID-19 Acute Respiratory Distress Syndrome. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 1489-1491.	2.5	38
543	Molecular detection of SARS-CoV-2 in formalin-fixed, paraffin-embedded specimens. JCI Insight, 2020, 5, .	2.3	80
544	Human angiotensin-converting enzyme 2 transgenic mice infected with SARS-CoV-2 develop severe and fatal respiratory disease. JCI Insight, 2020, 5, .	2.3	186
545	Virulence and pathogenesis of SARS-CoV-2 infection in rhesus macaques: A nonhuman primate model of COVID-19 progression. PLoS Pathogens, 2020, 16, e1008949.	2.1	76
546	mRNA induced expression of human angiotensin-converting enzyme 2 in mice for the study of the adaptive immune response to severe acute respiratory syndrome coronavirus 2. PLoS Pathogens, 2020, 16, e1009163.	2.1	24
547	COVID-19 therapy and prevention. Discoveries, 2020, 8, e113.	1.5	4
549	Mouse Model of SARS-CoV-2 Reveals Inflammatory Role of Type I Interferon Signaling. SSRN Electronic Journal, 2020, , 3628297.	0.4	3
550	COVID-19-like symptoms observed in Chinese tree shrews infected with SARS-CoV-2. Zoological Research, 2020, 41, 517-526.	0.9	49
551	Role of neutrophil chemoattractant CXCL5 in SARS-CoV-2 infection-induced lung inflammatory innate immune response in an <i>in vivo</i> hACE2 transfection mouse model. Zoological Research, 2020, 41, 621-631.	0.9	24
552	SARS, SARS again, and MERS. Review of animal models of human respiratory syndromes caused by coronavirus infections. Zhurnal Mikrobiologii Epidemiologii I Immunobiologii, 2020, 97, 431-444.	0.3	2
553	An insight into the use of transgenic animal models for conducting research on coronavirus. International Journal of Health & Allied Sciences, 2020, 9, 18.	0.0	1
554	Evaluation of the susceptibility of mice & hamsters to SARS-CoV-2 infection. Indian Journal of Medical Research, 2020, 151, 479.	0.4	25
555	Newly Emerging Human Coronaviruses: Animal Models and Vaccine Research for SARS, MERS, and COVID-19. Immune Network, 2020, 20, e28.	1.6	8
556	Evaluation of K18-hACE2 Mice as a Model of SARS-CoV-2 Infection. American Journal of Tropical Medicine and Hygiene, 2020, 103, 1215-1219.	0.6	140
557	Establishment of a nonhuman primate model for development of vaccines and anti-viral drugs against COVID-19. Translational and Regulatory Sciences, 2021, 3, 109-111.	0.2	0
558	Mouse Models for the Study of SARS-CoV-2 Infection. Comparative Medicine, 2021, 71, 383-397.	0.4	11
559	COVID-19 Vaccines: Adenoviral Vectors. Annual Review of Medicine, 2022, 73, 41-54.	5.0	46
560	Rapid development of analytical methods for evaluating pandemic vaccines: a COVID-19 perspective. Bioanalysis, 2021, 13, 1805-1826.	0.6	11

#	Article	IF	Citations
561	Review: Development of SARS-CoV-2 immuno-enhanced COVID-19 vaccines with nano-platform. Nano Research, 2022, 15, 2196-2225.	5.8	8
562	The gut microbiome as a biomarker of differential susceptibility to SARS-CoV-2. Trends in Molecular Medicine, 2021, 27, 1115-1134.	3.5	37
563	Rational preparation and application of a mRNA delivery system with cytidinyl/cationic lipid. Journal of Controlled Release, 2021, 340, 114-124.	4.8	11
564	Organoids as host models for infection biology â€“ a review of methods. Experimental and Molecular Medicine, 2021, 53, 1471-1482.	3.2	39
565	Mesenchymal Stromal Cells: an Antimicrobial and Host-Directed Therapy for Complex Infectious Diseases. Clinical Microbiology Reviews, 2021, 34, e0006421.	5.7	13
567	A potent bispecific nanobody protects hACE2 mice against SARS-CoV-2 infection via intranasal administration. Cell Reports, 2021, 37, 109869.	2.9	59
568	Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Dose, Infection, and Disease Outcomes for Coronavirus Disease 2019 (COVID-19): A Review. Clinical Infectious Diseases, 2022, 75, e1195-e1201.	2.9	13
569	Signaling pathways in the regulation of cytokine release syndrome in human diseases and intervention therapy. Signal Transduction and Targeted Therapy, 2021, 6, 367.	7.1	31
570	Engineering Extracellular Vesicles Enriched with Palmitoylated ACE2 as COVIDâ€19 Therapy. Advanced Materials, 2021, 33, e2103471.	11.1	60
571	Effect of Prophylactic Use of Intranasal Oil Formulations in the Hamster Model of COVID-19. Frontiers in Pharmacology, 2021, 12, 746729.	1.6	19
572	Abnormal Blood Coagulation and Kidney Damage in Aged Hamsters Infected with Severe Acute Respiratory Syndrome Coronavirus 2. Viruses, 2021, 13, 2137.	1.5	6
573	Mechanisms of Lung Injury Induced by SARS-CoV-2 Infection. Physiology, 2022, 37, 88-100.	1.6	18
574	Transmission dynamics and susceptibility patterns of SARSâ€CoVâ€2 in domestic, farmed and wild animals: Sustainable One Health surveillance for conservation and public health to prevent future epidemics and pandemics. Transboundary and Emerging Diseases, 2022, 69, 2523-2543.	1.3	16
575	Natural and Experimental SARS-CoV-2 Infection in Domestic and Wild Animals. Viruses, 2021, 13, 1993.	1.5	70
576	Emerging SARS-CoV-2 variants expand species tropism to murines. EBioMedicine, 2021, 73, 103643.	2.7	127
580	Bioinformatic evaluation of the potential animal models for studying SARS-Cov-2. Heliyon, 2020, 6, e05725.	1.4	3
581	Manganese nanodepot augments host immune response against coronavirus. Nano Research, 2021, 14, 1260-1272.	5.8	37
582	Narrative review of the novel coronavirus SARS-CoV-2: update on genomic characteristics, transmissions and animal model. Journal of Thoracic Disease, 2020, 12, 7454-7466.	0.6	1

#	Article	IF	Citations
585	Osteoclast-mediated bone loss observed in a COVID-19 mouse model. Bone, 2022, 154, 116227.	1.4	28
586	Natural Transmission and Experimental Models of SARSâ€'CoVâ€'2 Infection in Animals. Comparative Medicine, 2021, 71, 369-382.	0.4	2
587	Interspecies Jumping of Bat Coronaviruses. Viruses, 2021, 13, 2188.	1.5	16
588	The K18-Human ACE2 Transgenic Mouse Model Recapitulates Non-severe and Severe COVID-19 in Response to an Infectious Dose of the SARS-CoV-2 Virus. Journal of Virology, 2022, 96, JVI0096421.	1.5	84
589	Computational insights into differential interaction of mammalian angiotensin-converting enzyme 2 with the SARS-CoV-2 spike receptor binding domain. Computers in Biology and Medicine, 2022, 141, 105017.	3.9	11
591	Using in vivo animal models for studying SARS-CoV-2. Expert Opinion on Drug Discovery, 2022, 17, 121-137.	2.5	5
592	COVID-19 Anosmia: High Prevalence, Plural Neuropathogenic Mechanisms, and Scarce Neurotropism of SARS-CoV-2?. Viruses, 2021, 13, 2225.	1.5	25
593	Syrian hamsters as a model of lung injury with SARS-CoV-2 infection: Pathologic, physiologic, and detailed molecular profiling. Translational Research, 2022, 240, 1-16.	2.2	33
594	An Update on Animal Models for Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Countermeasure Development. Frontiers in Microbiology, 2021, 12, 770935.	1.5	4
595	Comparison of viral RNAâ€"host protein interactomes across pathogenic RNA viruses informs rapid antiviral drug discovery for SARS-CoV-2. Cell Research, 2022, 32, 9-23.	5.7	55
603	COVID-19 pandemic crisisâ€"a complete outline of SARS-CoV-2. Future Journal of Pharmaceutical Sciences, 2020, 6, 116.	1.1	2
605	An overview of preclinical animal models for SARS-CoV-2 pathogenicity. Indian Journal of Medical Research, 2021, 153, 17-25.	0.4	1
606	Lessons learned in stroke care during COVID-19 pandemic and preparing for future pandemics in the MENA+ region: A consensus statement from the MENA+-SINO. Journal of the Neurological Sciences, 2022, 432, 120060.	0.3	3
607	Receptome profiling identifies KREMEN1 and ASGR1 as alternative functional receptors of SARS-CoV-2. Cell Research, 2022, 32, 24-37.	5.7	98
608	Predicting the zoonotic capacity of mammals to transmit SARS-CoV-2. Proceedings of the Royal Society B: Biological Sciences, 2021, 288, 20211651.	1.2	53
609	Potential Applications and Perspectives of Humanized Mouse Models. Annual Review of Animal Biosciences, 2022, 10, 395-417.	3.6	18
611	Metformin Suppresses Monocyte Immunometabolic Activation by SARS-CoV-2 Spike Protein Subunit 1. Frontiers in Immunology, 2021, 12, 733921.	2.2	17
612	Animal models for SARSâ€CoVâ€2 infection and pathology. MedComm, 2021, 2, 548-568.	3.1	19

#	Article	IF	Citations
613	A defective viral genome strategy elicits broad protective immunity against respiratory viruses. Cell, 2021, 184, 6037-6051.e14.	13.5	33
614	Implications of testicular ACE2 and the reninâ€“angiotensin system for SARS-CoV-2 on testis function. Nature Reviews Urology, 2022, 19, 116-127.	1.9	29
616	Common Laboratory Mice Are Susceptible to Infection with the SARS-CoV-2 Beta Variant. Viruses, 2021, 13, 2263.	1.5	21
617	Neurological complications and infection mechanism of SARS-CoV-2. Signal Transduction and Targeted Therapy, 2021, 6, 406.	7.1	76
618	ACE2-like carboxypeptidase B38-CAP protects from SARS-CoV-2-induced lung injury. Nature Communications, 2021, 12, 6791.	5.8	32
619	Understanding COVID-19: From Dysregulated Immunity to Vaccination Status Quo. Frontiers in Immunology, 2021, 12, 765349.	2.2	5
621	A multitask transfer learning framework for the prediction of virus-human proteinâ€“protein interactions. BMC Bioinformatics, 2021, 22, 572.	1.2	16
622	Host parameters and mode of infection influence outcome in SARS-CoV-2 infected hamsters. IScience, 2021, 24, 103530.	1.9	12
623	SARS-CoV-2 at the human-animal interface: A review. Heliyon, 2021, 7, e08496.	1.4	9
624	Pannexin-1 channel opening is critical for COVID-19 pathogenesis. IScience, 2021, 24, 103478.	1.9	28
625	An overview of preclinical animal models for SARS-CoV-2 pathogenicity. Indian Journal of Medical Research, 2021, 153, 17.	0.4	4
626	Anosmia in COVID-19: Underlying Mechanisms and Assessment of an Olfactory Route to Brain Infection (Russian translation). Juvenis Scientia, 2021, 7, 28-59.	0.1	1
627	Effect of Jinzhen granule on two coronaviruses: The novel SARS-CoV-2 and the HCoV-229E and the evidences for their mechanisms of action. Phytomedicine, 2022, 95, 153874.	2.3	8
628	Absence of COVID-19-associated changes in plasma coagulation proteins and pulmonary thrombosis in the ferret model. Thrombosis Research, 2022, 210, 6-11.	0.8	3
629	Immune responses to human respiratory coronaviruses infection in mouse models. Current Opinion in Virology, 2022, 52, 102-111.	2.6	5
630	I. Animal Models of SARS-CoV-2 Infection and Pathogenesis. The Journal of the Japanese Society of Internal Medicine, 2020, 109, 2260-2263.	0.0	1
631	ACE2 Overexpressing Mesenchymal Stem Cells Alleviates COVID-19 Lung Injury by Inhibiting Pyroptosis. SSRN Electronic Journal, 0, , .	0.4	0
632	The cGASâ€“STING pathway drives type I IFN immunopathology in COVID-19. Nature, 2022, 603, 145-151.	13.7	272

#	Article	IF	Citations
633	Review on Drug Regulatory Science Promoting COVID-19 Vaccine Development in China. Engineering, 2022, 10, 127-132.	3.2	6
634	Lipopolysaccharide induces acute lung injury and alveolar haemorrhage in association with the cytokine storm, coagulopathy and AT1R/JAK/STAT augmentation in a rat modelÂthat mimics moderate and severe Covidâ€19 pathology. Clinical and Experimental Pharmacology and Physiology, 2022, 49, 483-491.	0.9	18
635	Vasculature-on-a-chip platform with innate immunity enables identification of angiopoietin-1 derived peptide as a therapeutic for SARS-CoV-2 induced inflammation. Lab on A Chip, 2022, 22, 1171-1186.	3.1	27
636	Animal Models of Human Pathology 2020. BioMed Research International, 2022, 2022, 1-2.	0.9	0
637	Comparison of Wild Type DNA Sequence of Spike Protein from SARS-CoV-2 with Optimized Sequence on The Induction of Protective Responses Against SARS-Cov-2 Challenge in Mouse Model. Human Vaccines and Immunotherapeutics, 2022, 18, 1-11.	1.4	2
638	Gene Therapy for Acute Respiratory Distress Syndrome. Frontiers in Physiology, 2021, 12, 786255.	1.3	4
639	Experimental Models of COVID-19. Frontiers in Cellular and Infection Microbiology, 2021, 11, 792584.	1.8	27
641	Human Organoids as a Promising Platform for Fighting COVID-19. International Journal of Biological Sciences, 2022, 18, 901-910.	2.6	3
642	Designing of a bispecific antibody against SARS-CoV-2 spike glycoprotein targeting human entry receptors DPP4 and ACE2. Human Immunology, 2022, 83, 346-355.	1.2	7
643	A lethal mouse model for evaluating vaccine-associated enhanced respiratory disease during SARS-CoV-2 infection. Science Advances, 2022, 8, eabh3827.	4.7	27
644	Communication Pattern Changes Along With Declined IGF1 of Immune Cells in COVID-19 Patients During Disease Progression. Frontiers in Immunology, 2021, 12, 729990.	2.2	3
645	Memory B cell repertoire from triple vaccinees against diverse SARS-CoV-2 variants. Nature, 2022, 603, 919-925.	13.7	146
646	The blood-brain barrier is dysregulated in COVID-19 and serves as a CNS entry route for SARS-CoV-2. Stem Cell Reports, 2022, 17, 307-320.	2.3	138
647	SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters. Nature, 2022, 603, 687-692.	13.7	475
648	SARS-CoV-2 Variants, Vaccines, and Host Immunity. Frontiers in Immunology, 2021, 12, 809244.	2.2	176
649	Systematic identification of ACE2 expression modulators reveals cardiomyopathy as a risk factor for mortality in COVID-19 patients. Genome Biology, 2022, 23, 15.	3.8	7
650	Age-dependent pathogenic characteristics of SARS-CoV-2 infection in ferrets. Nature Communications, 2022, 13, 21.	5.8	31
651	Type I interferons and SARS-CoV-2: from cells to organisms. Current Opinion in Immunology, 2022, 74, 172-182.	2.4	49

#	Article	IF	Citations
652	Anti-SARS-CoV-2 Efficacy of Elaeocarpus sylvestris Extract Verified by in silico, in vitro, Preclinical, and Clinical Studies. SSRN Electronic Journal, 0, , .	0.4	0
653	Animal models for SARS-CoV-2 and SARS-CoV-1 pathogenesis, transmission and therapeutic evaluation. World Journal of Virology, 2022, 11, 40-56.	1.3	9
654	Non-invasive administration of AAV to target lung parenchymal cells and develop SARS-CoV-2-susceptible mice. Molecular Therapy, 2022, 30, 1994-2004.	3.7	9
655	Comparative pathology of the nasal epithelium in K18-hACE2 Tg mice, hACE2 Tg mice, and hamsters infected with SARS-CoV-2. Veterinary Pathology, 2022, , 030098582110710.	0.8	12
656	SARS-CoV-2 treatment effects induced by ACE2-expressing microparticles are explained by the oxidized cholesterol-increased endosomal pH of alveolar macrophages. Cellular and Molecular Immunology, 2022, 19, 210-221.	4.8	15
657	In-vitro and In-vivo Experimental Models for MERS-CoV, SARS-CoV and SARS-CoV-2 Viral Infection: A Compendious Review. Recent Patents on Biotechnology, 2022, 16, .	0.4	1
658	The Effects of ATIR Blocker on the Severity of COVID-19 in Hypertensive Inpatients and Virulence of SARS-CoV-2 in Hypertensive hACE2 Transgenic Mice. Journal of Cardiovascular Translational Research, 2022, 15, 38-48.	1.1	3
659	SARS-CoV-2 membrane protein causes the mitochondrial apoptosis and pulmonary edema via targeting BOK. Cell Death and Differentiation, 2022, 29, 1395-1408.	5.0	39
660	Circulating ACE2-expressing extracellular vesicles block broad strains of SARS-CoV-2. Nature Communications, 2022, 13, 405.	5.8	92
662	Integrated histopathological, lipidomic, and metabolomic profiles reveal mink is a useful animal model to mimic the pathogenicity of severe COVID-19 patients. Signal Transduction and Targeted Therapy, 2022, 7, 29.	7.1	12
663	Human Organoids and Organsâ€onâ€Chips for Addressing COVIDâ€19 Challenges. Advanced Science, 2022, 9, e2105187.	5.6	19
664	Metrics to relate COVID-19 wastewater data to clinical testing dynamics. Water Research, 2022, 212, 118070.	5.3	68
667	A human antibody reveals a conserved site on beta-coronavirus spike proteins and confers protection against SARS-CoV-2 infection. Science Translational Medicine, 2022, 14, eabi9215.	5.8	123
668	Characterization of Two Heterogeneous Lethal Mouse-Adapted SARS-CoV-2 Variants Recapitulating Representative Aspects of Human COVID-19. Frontiers in Immunology, 2022, 13, 821664.	2.2	22
669	Diversity of Coronaviruses with Particular Attention to the Interspecies Transmission of SARS-CoV-2. Animals, 2022, 12, 378.	1.0	14
670	Tracking cryptic SARS-CoV-2 lineages detected in NYC wastewater. Nature Communications, 2022, 13, 635.	5.8	121
671	Modeling SARS-CoV-2 Infection in Mice Using Lentiviral hACE2 Vectors Infers Two Modes of Immune Responses to SARS-CoV-2 Infection. Viruses, 2022, 14, 11.	1.5	0
672	Novel SARS-CoV-2 receptors: ASGR1 and KREMEN1. Cell Research, 2022, 32, 1-2.	5.7	33

#	Article	IF	Citations
675	Infection of wild-type mice by SARS-CoV-2 B.1.351 variant indicates a possible novel cross-species transmission route. Signal Transduction and Targeted Therapy, 2021, 6, 420.	7.1	46
676	Pulmonary macrophages and SARS-Cov2 infection. International Review of Cell and Molecular Biology, 2022, 367, 1-28.	1.6	10
677	Sequentially immuneâ€induced antibodies could crossâ€neutralize SARSâ€CoVâ€2 variants. Animal Models and Experimental Medicine, 2022, 5, 89-93.	1.3	4
678	Structural Bases of Zoonotic and Zooanthroponotic Transmission of SARS-CoV-2. Viruses, 2022, 14, 418.	1.5	8
680	A Simplified SARS-CoV-2 Mouse Model Demonstrates Protection by an Oral Replicon-Based mRNA Vaccine. Frontiers in Immunology, 2022, 13, 811802.	2.2	8
681	COVID-19 mRNA vaccines: Platforms and current developments. Molecular Therapy, 2022, 30, 1850-1868.	3.7	102
682	Microglia Do Not Restrict SARS-CoV-2 Replication following Infection of the Central Nervous System of K18-Human ACE2 Transgenic Mice. Journal of Virology, 2022, 96, jvi0196921.	1.5	18
683	Targeting Mononuclear Phagocytes to Treat COVID-19. , 0, , .		0
684	Diabetes and COVID-19; A Bidirectional Interplay. Frontiers in Endocrinology, 2022, 13, 780663.	1.5	38
685	Innate Immune Response in SARS-CoV-2 Infection. Microorganisms, 2022, 10, 501.	1.6	13
686	Identification of cell type specific ACE2 modifiers by CRISPR screening. PLoS Pathogens, 2022, 18, e1010377.	2.1	9
687	Eicosanoid signalling blockade protects middle-aged mice from severe COVID-19. Nature, 2022, 605, 146-151.	13.7	82
688	Infection with the SARS-CoV-2 B.1.351 variant is lethal in aged BALB/c mice. Scientific Reports, 2022, 12, 4150.	1.6	9
689	Short-Term Instantaneous Prophylaxis and Efficient Treatment Against SARS-CoV-2 in hACE2 Mice Conferred by an Intranasal Nanobody (Nb22). Frontiers in Immunology, 2022, 13, 865401.	2.2	8
690	Development of off-the-shelf hematopoietic stem cell-engineered invariant natural killer T cells for COVID-19 therapeutic intervention. Stem Cell Research and Therapy, 2022, 13, 112.	2.4	14
691	Crosstalk between SARS-CoV-2 Infection and Type II Diabetes. Combinatorial Chemistry and High Throughput Screening, 2022, 25, 2429-2442.	0.6	1
692	A rare case of reactive granulomatous dermatitis during COVIDâ€19: a possible role of cephalosporine and potential mechanisms. Journal of the European Academy of Dermatology and Venereology, 2022, 36, .	1.3	0
693	Transcriptome Analysis of Lungs in a Mouse Model of Severe COVID-19. Frontiers in Virology, 2022, 2, .	0.7	3

#	Article	IF	Citations
694	Thinking Outside the Box: Utilizing Nontraditional Animal Models for COVID-19 Research. International Journal of Translational Medicine, 2022, 2, 113-133.	0.1	2
695	Transmissibility and pathogenicity of SARS-CoV-2 variants in animal models. Journal of Microbiology, 2022, 60, 255-267.	1.3	9
697	Review of selected animal models for respiratory coronavirus infection and its application in drug research. Journal of Medical Virology, 2022, , .	2.5	5
698	Systematic Tracing of Susceptible Animals to SARS-CoV-2 by a Bioinformatics Framework. Frontiers in Microbiology, 2022, 13, 781770.	1.5	4
700	Human Organotypic Airway and Lung Organoid Cells of Bronchiolar and Alveolar Differentiation Are Permissive to Infection by Influenza and SARS-CoV-2 Respiratory Virus. Frontiers in Cellular and Infection Microbiology, 2022, 12, 841447.	1.8	17
701	Mild SARS-CoV-2 infection in rhesus macaques is associated with viral control prior to antigen-specific T cell responses in tissues. Science Immunology, 2022, 7, eabo0535.	5.6	17
702	Animal models in SARS-CoV-2 research. Nature Methods, 2022, 19, 392-394.	9.0	51
703	Consequences of Viral Infection and Cytokine Production During Pregnancy on Brain Development in Offspring. Frontiers in Immunology, 2022, 13, 816619.	2.2	15
704	A potent human monoclonal antibody with pan-neutralizing activities directly dislocates S trimer of SARS-CoV-2 through binding both up and down forms of RBD. Signal Transduction and Targeted Therapy, 2022, 7, 114.	7.1	17
705	ACE2 overexpressing mesenchymal stem cells alleviates COVID-19 lung injury by inhibiting pyroptosis. IScience, 2022, 25, 104046.	1.9	4
706	Comprehensive Oncogenic Features of Coronavirus Receptors in Glioblastoma Multiforme. Frontiers in Immunology, 2022, 13, 840785.	2.2	8
707	Liushen Capsules, a promising clinical candidate for COVID-19, alleviates SARS-CoV-2-induced pulmonary in vivo and inhibits the proliferation of the variant virus strains in vitro. Chinese Medicine, 2022, 17, 40.	1.6	8
708	Exploring the inhibitory potential of Saussurea costus and Saussurea involucrata phytoconstituents against the Spike glycoprotein receptor binding domain of SARS-CoV-2 Delta (B.1.617.2) variant and the main protease (Mpro) as therapeutic candidates, using Molecular docking, DFT, and ADME/Tox studies. Journal of Molecular Structure, 2022, 1263, 133032.	1.8	14
709	Hyper/neuroinflammation in COVID-19 and suicide etiopathogenesis: Hypothesis for a nefarious collision?. Neuroscience and Biobehavioral Reviews, 2022, 136, 104606.	2.9	15
710	Mesenchymal stem/stromal cell-based therapies for severe viral pneumonia: therapeutic potential and challenges. Intensive Care Medicine Experimental, 2021, 9, 61.	0.9	9
711	Drug repurposing and other strategies for rapid coronavirus antiviral development: lessons from the early stage of the COVID-19 pandemic. , 2021, , 39-68.		0
713	Chronological brain lesions after SARS-CoV-2 infection in hACE2-transgenic mice. Veterinary Pathology, 2022, 59, 613-626.	0.8	37
714	State-of-the-art preclinical evaluation of COVID-19 vaccine candidates. Exploration of Immunology, 0, , 440-460.	1.7	0

#	Article	IF	Citations
715	Editorial: Ethnopharmacological Responses to the Coronavirus Disease 2019 Pandemic. Frontiers in Pharmacology, 2021, 12, 798674.	1.6	5
716	Techniques for Developing and Assessing Immune Responses Induced by Synthetic DNA Vaccines for Emerging Infectious Diseases. Methods in Molecular Biology, 2022, 2410, 229-263.	0.4	1
717	Foxp3+ CD4+ regulatory T cells control dendritic cells in inducing antigen-specific immunity to emerging SARS-CoV-2 antigens. PLoS Pathogens, 2021, 17, e1010085.	2.1	13
718	A humanized mouse model of chronic COVID-19. Nature Biotechnology, 2022, 40, 906-920.	9.4	71
720	Sequential immunizations confer cross-protection against variants of SARS-CoV-2, including Omicron in Rhesus macaques. Signal Transduction and Targeted Therapy, 2022, 7, 124.	7.1	15
722	A retrospective study on the effect of the COVID-19 pandemic on dental treatments in adults. BMC Oral Health, 2022, 22, 122.	0.8	5
726	Treatment of SARS-CoV-2-induced pneumonia with NAD+ and NMN in two mouse models. Cell Discovery, 2022, 8, 38.	3.1	24
727	SARS-CoV-2 Droplet and Airborne Transmission Heterogeneity. Journal of Clinical Medicine, 2022, 11, 2607.	1.0	9
728	Application of animal models to compare and contrast the virulence of current and future potential SARS-CoV-2 variants. Biosafety and Health, 2022, 4, 154-160.	1.2	3
729	Lung Aeration in COVID-19 Pneumonia by Ultrasonography and Computed Tomography. Journal of Clinical Medicine, 2022, 11, 2718.	1.0	3
731	ADAM10 and ADAM17 promote SARSâ€CoVâ€2 cell entry and spike proteinâ€mediated lung cell fusion. EMBO Reports, 2022, 23, e54305.	2.0	57
732	Advances in Modelling COVID-19 in Animals. Frontiers in Drug Discovery, 2022, 2, .	1.1	0
733	A Multi-dimensional Review on Severe Acute Respiratory Syndrome CoronaVirus-2. Current Pharmaceutical Biotechnology, 2022, 23, .	0.9	1
734	Heterogeneous Infectivity and Pathogenesis of SARS-CoV-2 Variants Beta, Delta and Omicron in Transgenic K18-hACE2 and Wildtype Mice. Frontiers in Microbiology, 2022, 13, .	1.5	39
735	Animal Models of COVID-19: Transgenic Mouse Model. Methods in Molecular Biology, 2022, 2452, 259-289.	0.4	14
736	Lethal synergy between SARS-CoV-2 and Streptococcus pneumoniae in hACE2 mice and protective efficacy of vaccination. JCI Insight, 2022, 7, .	2.3	14
737	Potential intestinal infection and faecalâ€oral transmission of human coronaviruses. Reviews in Medical Virology, 2022, 32, e2363.	3.9	3
738	Inhibition of IRAK4 dysregulates SARS-CoV-2 spike protein-induced macrophage inflammatory and glycolytic reprogramming. Cellular and Molecular Life Sciences, 2022, 79, 301.	2.4	9

#	Article	IF	Citations
739	Caspase-4/11 exacerbates disease severity in SARSâ€“CoV-2 infection by promoting inflammation and immunothrombosis. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, e2202012119.	3.3	25
740	Mechanisms involved in controlling RNA virus-induced intestinal inflammation. Cellular and Molecular Life Sciences, 2022, 79, .	2.4	8
741	Pyronaridine Protects against SARS-CoV-2 Infection in Mouse. ACS Infectious Diseases, 2022, 8, 1147-1160.	1.8	14
742	Characterization of Immune Response Diversity in Rodents Vaccinated with a Vesicular Stomatitis Virus Vectored COVID-19 Vaccine. Viruses, 2022, 14, 1127.	1.5	7
744	The Association of Covid-19 Outbreak with Cancer Patients. Pakistan Biomedical Journal, 0, , 38-43.	0.0	0
745	HDAC inhibitors against SARS-CoV-2. Letters in Drug Design and Discovery, 2022, 19, .	0.4	0
747	Recombinant chimpanzee adenovirus vector vaccine expressing the spike protein provides effective and lasting protection against SARS-CoV-2 infection in mice. Virologica Sinica, 2022, , .	1.2	0
748	Mouse models in COVID-19 research: analyzing the adaptive immune response. Medical Microbiology and Immunology, 2023, 212, 165-183.	2.6	6
750	Pathogenesis of SARS-CoV-2 and Mycobacterium tuberculosis Coinfection. Frontiers in Immunology, 0, 13, .	2.2	13
751	Cytokines and Lipid Mediators of Inflammation in Lungs of SARS-CoV-2 Infected Mice. Frontiers in Immunology, 0, 13, .	2.2	10
752	Development of an efficient reproducible cell-cell transmission assay for rapid quantification of SARS-CoV-2 Spike interaction with hACE2. Cell Reports Methods, 2022, , 100252.	1.4	1
753	Identification and characterization of the anti-SARS-CoV-2 activity of cationic amphiphilic steroidal compounds. Virulence, 2022, 13, 1031-1048.	1.8	2
754	Nanoarchitectonics: role of nanomaterials in vaccination strategies for curbing SARs-CoV-2/COVID-19. Nanofabrication, 0, 7, .	1.1	0
755	Safety and protective capability of an inactivated SARS-CoV-2 vaccine on pregnancy, lactation and the growth of offspring in hACE2 mice. Vaccine, 2022, 40, 4609-4616.	1.7	8
756	A modified porous silicon microparticle potentiates protective systemic and mucosal immunity for SARS-CoV-2 subunit vaccine. Translational Research, 2022, 249, 13-27.	2.2	5
757	Animal Models for COVID-19 Therapeutic Development: Where We Are and Where We Need to Go. Frontiers in Microbiology, 0, 13, .	1.5	7
758	Food as a countermeasure to SARS-COV-2. Science Technologies Innovation, 2022, , 36-46.	0.1	0
759	Experimental Models of SARS-COV-2 Infection in the Central Nervous System. Journal of Central Nervous System Disease, 2022, 14, 117957352211022.	0.7	0

#	Article	IF	Citations
760	Natural and genetically-modified animal models to investigate pulmonary and extrapulmonary manifestations of COVID-19. International Reviews of Immunology, 2024, 43, 13-32.	1.5	3
761	Laboratory information management system for COVID-19 non-clinical efficacy trial data. Laboratory Animal Research, 2022, 38, .	1.1	1
762	Antiparasitic Drugs against SARS-CoV-2: A Comprehensive Literature Survey. Microorganisms, 2022, 10, 1284.	1.6	2
763	Development of a novel human CD147 knock-in NSG mouse model to test SARS-CoV-2 viral infection. Cell and Bioscience, 2022, 12, .	2.1	7
764	Celecoxib Microparticles for Inhalation in COVID-19-Related Acute Respiratory Distress Syndrome. Pharmaceutics, 2022, 14, 1392.	2.0	5
766	Immune determinants of chronic sequelae after respiratory viral infection. Science Immunology, 2022, 7, .	5.6	18
767	Cell and Animal Models for SARS-CoV-2 Research. Viruses, 2022, 14, 1507.	1.5	9
768	Creation of transgenic mice susceptible to coronaviruses: a platform for studying viral pathogenesis and testing vaccines. Vavilovskii Zhurnal Genetiki I Selektsii, 2022, 26, 402-408.	0.4	0
769	Gasdermin-D activation by SARS-CoV-2 triggers NET and mediate COVID-19 immunopathology. Critical Care, 2022, 26, .	2.5	38
770	Carbohydrates Metabolic Signatures in Immune Cells: Response to Infection. Frontiers in Immunology, 0, 13, .	2.2	2
771	Animal models for COVID-19: advances, gaps and perspectives. Signal Transduction and Targeted Therapy, 2022, 7, .	7.1	40
772	De Novo-Whole Genome Assembly of the Roborovski Dwarf Hamster (Phodopus roborovskii) Genome: An Animal Model for Severe/Critical COVID-19. Genome Biology and Evolution, 2022, 14, .	1.1	4
773	Cognitive Assessment in SARS-CoV-2 Patients: A Systematic Review. Frontiers in Aging Neuroscience, 0, 14, .	1.7	21
774	Proteomic and Metabolomic Characterization of SARS-CoV-2-Infected Cynomolgus Macaque at Early Stage. Frontiers in Immunology, 0, 13, .	2.2	3
775	Significance of chlorineâ€dioxideâ€based oral rinses in preventing <scp>SARSâ€CoV</scp>â€2 cell entry. Oral Diseases, 2022, 28, 2481-2491.	1.5	3
776	Frequent detection but lack of infectivity of SARS-CoV-2 RNA in presymptomatic, infected blood donor plasma. Journal of Clinical Investigation, 2022, 132, .	3.9	16
777	SARS-CoV-2 and the Missing Link of Intermediate Hosts in Viral Emergence - What We Can Learn From Other Betacoronaviruses. Frontiers in Virology, 0, 2, .	0.7	3
778	Cell tropism and viral clearance during SARS-CoV-2 lung infection. Pathology Research and Practice, 2022, 236, 154000.	1.0	3

#	Article	IF	Citations
779	Nasal Mucosa Exploited by SARS-CoV-2 for Replicating and Shedding during Reinfection. Viruses, 2022, 14, 1608.	1.5	2
780	Angiotensin-(1â€“9) in hypertension. Biochemical Pharmacology, 2022, 203, 115183.	2.0	6
781	Serosurvey for SARS-CoV-2 among blood donors in Wuhan, China from September to December 2019. Protein and Cell, 0, , .	4.8	6
782	A history of coronaviruses. WikiJournal of Medicine, 2022, 9, 5.	1.0	0
783	Cambios en salud durante la pandemia por COVID-19 en estudiantes universitarios. AproximaciÃ³n reflexiva a la luz de la dimensiÃ³n emocional. Alìgora, 2022, 9, 58-64.	0.0	0
784	Development of transgenic models susceptible and resistant to SARS-CoV-2 infection in FVB background mice. PLoS ONE, 2022, 17, e0272019.	1.1	2
785	Exercise-induced myokines downregulates the ACE2 level in bronchial epithelial cells: Implications for SARS-CoV-2 prevention. PLoS ONE, 2022, 17, e0271303.	1.1	5
786	Human organoids: New strategies and methods for analyzing human development and disease. Cell, 2022, 185, 2756-2769.	13.5	42
787	Early Isolates of SARS-CoV-2 Result in Different Pathogenesis in the Transduced Mouse Model of COVID-19. Viruses, 2022, 14, 1769.	1.5	1
788	Characterization of Entry Pathways, Species-Specific Angiotensin-Converting Enzyme 2 Residues Determining Entry, and Antibody Neutralization Evasion of Omicron BA.1, BA.1.1, BA.2, and BA.3 Variants. Journal of Virology, 2022, 96, .	1.5	12
789	Molecular mechanisms involved in anosmia induced by SARS-CoV-2, with a focus on the transmembrane serine protease TMPRSS2. Archives of Virology, 2022, 167, 1931-1946.	0.9	13
790	APOE interacts with ACE2 inhibiting SARS-CoV-2 cellular entry and inflammation in COVID-19 patients. Signal Transduction and Targeted Therapy, 2022, 7, .	7.1	26
791	Humanized mice for investigating SARSâ€CoVâ€2 lung infection and associated human immune responses. European Journal of Immunology, 2022, 52, 1640-1647.	1.6	3
792	Development of a novel peptide to prevent entry of SARS-CoV-2 into lung and olfactory bulb cells of hACE2 expressing mice. Molecular Brain, 2022, 15, .	1.3	1
793	Immunogenicity and protectivity of intranasally delivered vector-based heterologous prime-boost COVID-19 vaccine Sputnik V in mice and non-human primates. Emerging Microbes and Infections, 2022, 11, 2229-2247.	3.0	8
794	COVID-19: A Veterinary and One Health Perspective. Journal of the Indian Institute of Science, 2022, 102, 689-709.	0.9	2
795	A SCID Mouse Model To Evaluate the Efficacy of Antivirals against SARS-CoV-2 Infection. Journal of Virology, 2022, 96, .	1.5	5
796	Most frequently harboured missense variants of hACE2 across different populations exhibit varying patterns of binding interaction with spike glycoproteins of emerging SARS-CoV-2 of different lineages. Computers in Biology and Medicine, 2022, 148, 105903.	3.9	5

#	Article	IF	Citations
797	Obesity and metabolic dysfunction drive sex-associated differential disease profiles in hACE2-mice challenged with SARS-CoV-2. IScience, 2022, 25, 105038.	1.9	9
798	Global distribution of ACE1 (rs4646994) and ACE2 (rs2285666) polymorphisms associated with COVID-19: A systematic review and meta-analysis. Microbial Pathogenesis, 2022, 172, 105781.	1.3	6
799	Minimum infective dose of severe acute respiratory syndrome coronavirus 2 based on the current evidence: A systematic review. SAGE Open Medicine, 2022, 10, 205031212211150.	0.7	9
800	Traditional Chinese medicines against COVID-19: A global overview. World Journal of Traditional Chinese Medicine, 2022, 8, 279.	0.9	13
801	Enoxaparin Improves COVID-19 by Reducing Neutrophils Extracellular Traps (NETS) Production. SSRN Electronic Journal, 0, , .	0.4	0
802	Microglia in antiviral immunity of the brain and spinal cord. Seminars in Immunology, 2022, 60, 101650.	2.7	1
803	Inhibition of MEK signaling prevents SARSâ€CoV2â€induced lung damage and improves the survival of infected mice. Journal of Medical Virology, 2022, 94, 6097-6102.	2.5	3
804	Vandetanib Blocks the Cytokine Storm in SARS-CoV-2-Infected Mice. ACS Omega, 2022, 7, 31935-31944.	1.6	11
805	SARSâ€CoVâ€2 does not infect pigs, but this has to be verified regularly. Xenotransplantation, 2022, 29, .	1.6	3
806	Clinical characteristics and outcomes of lung cancer patients with COVID-19: A systematic review and meta-analysis protocol. PLoS ONE, 2022, 17, e0273691.	1.1	1
807	After the virus has clearedâ€"Can preclinical models be employed for Long COVID research?. PLoS Pathogens, 2022, 18, e1010741.	2.1	10
808	Potential mouse models of coronavirus-related immune injury. Frontiers in Immunology, 0, 13, .	2.2	1
810	In silico analysis of the conserved surface-exposed epitopes to design novel multiepitope peptide vaccine for all variants of the SARS-CoV-2. Journal of Biomolecular Structure and Dynamics, 2023, 41, 7603-7615.	2.0	4
811	Prospects of animal models and their application in studies on adaptive immunity to SARS-CoV-2. Frontiers in Immunology, 0, 13, .	2.2	4
812	Mucosal nanobody IgA as inhalable and affordable prophylactic and therapeutic treatment against SARS-CoV-2 and emerging variants. Frontiers in Immunology, 0, 13, .	2.2	5
813	Renessans Helps in Early Clearance of SARS-CoV-2: In-Vivo Activity of the Iodine Complex in Rhesus macaque. Life, 2022, 12, 1424.	1.1	1
814	Spike protein-independent attenuation of SARS-CoV-2 Omicron variant in laboratory mice. Cell Reports, 2022, 40, 111359.	2.9	23
815	Mouse models of COVID-19 recapitulate inflammatory pathways rather than gene expression. PLoS Pathogens, 2022, 18, e1010867.	2.1	17

#	Article	IF	Citations
816	Gut as an Alternative Entry Route for SARS-CoV-2: Current Evidence and Uncertainties of Productive Enteric Infection in COVID-19. Journal of Clinical Medicine, 2022, 11, 5691.	1.0	10
817	SARS-CoV-2 Delta and Omicron variants evade population antibody response by mutations in a single spike epitope. Nature Microbiology, 2022, 7, 1635-1649.	5.9	25
818	Ä°NSANLARDAKÄ° COVID-19 YABAN HAYVANLARINDA RÄ°SK OLUÅžTURUYOR MU?. Ìİzmir Democracy University Health Sciences Journal, 0, , .	0.4	0
819	Sequence difference of angiotensin-converting enzyme 2 between nonhuman primates affects its binding-affinity with SARS-CoV-2 S receptor binding domain. Biosafety and Health, 2022, , .	1.2	0
820	COVID-19 and cellular senescence. Nature Reviews Immunology, 2023, 23, 251-263.	10.6	54
821	A storm in a teacup -- A biomimetic lung microphysiological system in conjunction with a deep-learning algorithm to monitor lung pathological and inflammatory reactions. Biosensors and Bioelectronics, 2023, 219, 114772.	5.3	6
822	The interplay between the airway epithelium and tissue macrophages during the SARS-CoV-2 infection. Frontiers in Immunology, 0, 13, .	2.2	5
823	SARS CoV-2 infections in animals, two years into the pandemic. Archives of Virology, 2022, 167, 2503-2517.	0.9	19
824	Engagement of scientists with the public and policymakers to promote alternative methods. ALTEX: Alternatives To Animal Experimentation, 2022, , 543-559.	0.9	2
825	Comparison of the pathogenesis of SARS-CoV-2 infection in K18-hACE2 mouse and Syrian golden hamster models. DMM Disease Models and Mechanisms, 2022, 15, .	1.2	14
826	Neuroâ€“Immune Interactions in Severe COVID-19 Infection. Pathogens, 2022, 11, 1256.	1.2	1
827	SARS-CoV-2 Variant-Specific Infectivity and Immune Profiles Are Detectable in a Humanized Lung Mouse Model. Viruses, 2022, 14, 2272.	1.5	3
828	Improved control of SARS-CoV-2 by treatment with a nucleocapsid-specific monoclonal antibody. Journal of Clinical Investigation, 2022, 132, .	3.9	33
829	Influenza Infection in Ferrets with SARS-CoV-2 Infection History. Microbiology Spectrum, 0, , .	1.2	0
830	Characteristics of animal models for COVIDâ€19. Animal Models and Experimental Medicine, 2022, 5, 401-409.	1.3	7
831	Zebrafish models of COVID-19. FEMS Microbiology Reviews, 2023, 47, .	3.9	6
832	Gut microbiome dysbiosis in antibiotic-treated COVID-19 patients is associated with microbial translocation and bacteremia. Nature Communications, 2022, 13, .	5.8	67
833	SARS-CoV-2 drives NLRP3 inflammasome activation in human microglia through spike protein. Molecular Psychiatry, 2023, 28, 2878-2893.	4.1	47

#	Article	IF	Citations
834	Temporal Transcriptome Analysis of SARS-CoV-2-Infected Lung and Spleen in Human ACE2-Transgenic Mice. Molecules and Cells, 2022, 45, 896-910.	1.0	0
835	Intranasal delivery of a rationally attenuated SARS-CoV-2 is immunogenic and protective in Syrian hamsters. Nature Communications, 2022, 13, .	5.8	11
836	Success of nano-vaccines against COVID-19: a transformation in nanomedicine. Expert Review of Vaccines, 2022, 21, 1739-1761.	2.0	2
837	A minimally-edited mouse model for infection with multiple SARS-CoV-2 strains. Frontiers in Immunology, 0, 13, .	2.2	3
838	Autocrine, Paracrine, and Endocrine Signals That Can Alter Alveolar Macrophages Function. Reviews of Physiology, Biochemistry and Pharmacology, 2022, , .	0.9	0
839	Phenothiazines inhibit SARS-CoV-2 cell entry via a blockade of spike protein binding to neuropilin-1. Antiviral Research, 2023, 209, 105481.	1.9	13
840	Comparative study of Wuhan-like and omicron-like variants of SARS-CoV-2 in experimental animal models. Voprosy Virusologii, 2022, 67, 439-449.	0.1	0
841	Infection of SARS-CoV-2 causes severe pathological changes in mouse testis. Journal of Genetics and Genomics, 2023, 50, 99-107.	1.7	4
842	Neurotropism and blood-brain barrier involvement in COVID-19. Frontiers in Drug Delivery, 0, 2, .	0.4	2
843	Rational identification of potent and broad sarbecovirus-neutralizing antibody cocktails from SARS convalescents. Cell Reports, 2022, 41, 111845.	2.9	46
844	Viral Zoonotic Diseases of Public Health Importance and Their Effect on Male Reproduction. , 2022, 2, 291-300.		1
846	Macrophages and Î³Î´ T cells interplay during SARS-CoV-2 variants infection. Frontiers in Immunology, 0, 13, .	2.2	5
847	Animal Models to Test SARS-CoV-2 Vaccines: Which Ones Are in Use and Future Expectations. Pathogens, 2023, 12, 20.	1.2	4
848	Susceptibility of SARS Coronavirus-2 infection in domestic and wild animals: a systematic review. 3 Biotech, 2023, 13, .	1.1	6
850	Establishment of multicenter COVID-19 therapeutics preclinical test system in Republic of Korea. Pulmonary Pharmacology and Therapeutics, 2023, , 102189.	1.1	0
851	SARS-CoV-2 variants induce distinct disease and impact in the bone marrow and thymus of mice. IScience, 2023, 26, 105972.	1.9	3
852	Preclinical studies of antiviral activity of the RPH-137 fusion protein and molnupiravir against COVID-19. BIOpreparations Prevention Diagnosis Treatment, 2022, 22, 414-434.	0.2	1
853	Monoclonal Antibodies Specific for SARS-CoV-2 Spike Protein Suitable for Multiple Applications for Current Variants of Concern. Viruses, 2023, 15, 139.	1.5	8

#	Article	IF	Citations
854	Clinical characteristics and remission of nine cases with coronavirus disease 2019 infection in Zunyi, Southwest of China: A retrospective study. Medicine (United States), 2022, 101, e31494.	0.4	0
855	Generation and Characterization of a SARS-CoV-2-Susceptible Mouse Model Using Adeno-Associated Virus (AAV6.2FF)-Mediated Respiratory Delivery of the Human ACE2 Gene. Viruses, 2023, 15, 85.	1.5	2
856	Animal models and SARS-CoV-2-induced pulmonary and neurological injuries. Memorias Do Instituto Oswaldo Cruz, 0, 117, .	0.8	0
857	Comparison of Cardiovascular Pathology in Animal Models of SARS-CoV-2 Infection: Recommendations Regarding Standardization of Research Methods. Comparative Medicine, 2023, , .	0.4	1
858	Ocular Symptoms Associated with COVID-19 Are Correlated with the Expression Profile of Mouse SARS-CoV-2 Binding Sites. Viruses, 2023, 15, 354.	1.5	0
859	A SARS-CoV-2-Related Virus from Malayan Pangolin Causes Lung Infection without Severe Disease in Human ACE2-Transgenic Mice. Journal of Virology, 2023, 97, .	1.5	11
860	Animal Models for the Study of Neurologic Manifestations Of COVID-19. Comparative Medicine, 2023, 73, 91-103.	0.4	2
862	Animal models of COVID-19 and complications. , 2023, , 623-636.		0
863	In silico disease modeling for COVID-19. , 2023, , 291-299.		0
865	Characterization of a Vesicular Stomatitis Virus-Vectored Recombinant Virus Bearing Spike Protein of SARS-CoV-2 Delta Variant. Microorganisms, 2023, 11, 431.	1.6	1
866	Comparison of the replication and neutralization of different <scp>SARSâ€CoV</scp> â€2 Omicron subvariants in vitro. Animal Models and Experimental Medicine, 2023, 6, 51-56.	1.3	2
867	Identification of the regulatory mechanism of ACE2 in COVID-19â€“induced kidney damage with systems genetics approach. Journal of Molecular Medicine, 2023, 101, 449-460.	1.7	2
868	Functionalized protein microparticles targeting hACE2 as a novel preventive strategy for SARS-CoV-2 infection. International Journal of Pharmaceutics, 2023, 638, 122921.	2.6	0
869	Development and applications of mRNA treatment based on lipid nanoparticles. Biotechnology Advances, 2023, 65, 108130.	6.0	10
871	Prophylaxis and treatment of SARS-CoV-2 infection by an ACE2 receptor decoy in a preclinical animal model. IScience, 2023, 26, 106092.	1.9	5
872	Susceptibility of domestic and companion animals to SARS-CoV-2: a comprehensive review. Tropical Animal Health and Production, 2023, 55, .	0.5	3
873	Mouse-Adapted SARS-CoV-2 MA10 Strain Displays Differential Pulmonary Tropism and Accelerated Viral Replication, Neurodissemination, and Pulmonary Host Responses in K18-hACE2 Mice. MSphere, 2023, 8, .	1.3	3
875	Cell-autonomous requirement for ACE2 across organs in lethal mouse SARS-CoV-2 infection. PLoS Biology, 2023, 21, e3001989.	2.6	6

#	Article	IF	Citations
876	Development of animal models for emerging infectious diseases by breaking the barrier of species susceptibility to human pathogens. Emerging Microbes and Infections, 2023, 12, .	3.0	1
877	Induced Pluripotent Stem Cell-Derived Organoids: Their Implication in COVID-19 Modeling. International Journal of Molecular Sciences, 2023, 24, 3459.	1.8	1
879	An acute respiratory distress syndrome drug development collaboration stimulated by the Virginia Drug Discovery Consortium. SLAS Discovery, 2023, , .	1.4	1
880	Animal Models, Zoonotic Reservoirs, and Cross-Species Transmission of Emerging Human-Infecting Coronaviruses. Annual Review of Animal Biosciences, 2023, 11, 1-31.	3.6	8
881	Ferrets: A powerful model of SARS-CoV-2. Zoological Research, 2023, 44, 323-330.	0.9	1
882	Transgenic animal models for the functional analysis of ACE2. , 2023, , 491-503.		0
883	Autophagy in Inflammatory Response against SARS-CoV-2. International Journal of Molecular Sciences, 2023, 24, 4928.	1.8	4
885	Application of Pseudotyped Viruses. Advances in Experimental Medicine and Biology, 2023, , 45-60.	0.8	2
886	Proteomic and phosphoproteomic characteristics of the cortex, hippocampus, thalamus, lung, and kidney in COVID-19-infected female K18-hACE2 mice. EBioMedicine, 2023, 90, 104518.	2.7	1
887	At the crossroads of epidemiology and biology: Bridging the gap between SARS-CoV-2 viral strain properties and epidemic wave characteristics. Biochimie, 2023, 213, 54-65.	1.3	0
889	Comparison and monitoring of antibody response in convalescent and healthy vaccinated individuals against RBD and PCS of SARS-CoV-2 spike protein. Journal of Biomolecular Structure and Dynamics, 0, , 1-8.	2.0	0
890	Cryo-EM structures and binding of mouse and human ACE2 to SARS-CoV-2 variants of concern indicate that mutations enabling immune escape could expand host range. PLoS Pathogens, 2023, 19, e1011206.	2.1	8
891	Interferon-dependent signaling is critical for viral clearance in airway neutrophils. JCI Insight, 2023, 8, .	2.3	4
892	Targeting the Viral Entry Pathways through Repurposed Drugs in Sars-Cov-2 Infection. , 2023, , 72-99.		0
899	Accelerating antiviral drug discovery: lessons from COVID-19. Nature Reviews Drug Discovery, 2023, 22, 585-603.	21.5	25
901	â€œPandemics-on-a-Chipâ€• Organ-on-a-Chip Models for Studying Viral Infections. , 2023, , 133-157.		0
902	Methods in Drug Repurposing: Emphasis on COVID-19. , 2023, , 111-126.		0
914	Disease Models in Viral Research. , 2023, , 215-239.		0

#	Article	IF	Citations
935	In Vivo Models for Evaluation of Drug Efficacy: Demand and Challenges. , 2023, , 113-147.		0
973	Genetically modified mice as a tool for the study of human diseases. Molecular Biology Reports, 2024, 51, .	1.0	0
982	Animal Models for Infectious Disease Vaccine Development. , 2024, , 791-847.		0
988	Histopathology assay of the lung after intratracheal injection of SARS-CoV-2 spike protein recombinant in mice: A preliminary study. AIP Conference Proceedings, 2024, , .	0.3	0